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Clinical and preclinical pharmacology of the antioxidant flavonoid 
7-mono-O-(β-hydroxyethyl)-rutoside (monoHER) 
Chemical structure and antioxidant properties of monoHER 
7-mono-O-(β-hydroxyethyl)-rutoside (monoHER) is a semisynthetic flavonoid 
and a constituent of Venoruton, a registered drug that is used in the treatment 
for chronic venous insufficiency. Venoruton also contains other structurally 
related hydroxyethylrutosides (HERs), i.e. diHER, triHER and tetraHER. These 
HERs are derived from the naturally occurring flavonoid rutin by substituting its 
hydroxyl groups with O-β-hydroxyethyl groups. Of these semisynthetic flavono-
ids, monoHER appeared to be the most powerful antioxidant (Haenen et al., 
1993; van Acker et al., 1993). 
Like most flavonoids, monoHER consists of three rings referred to as the A, 
B and C rings (Figure 1). In addition, it contains an ortho-dihydroxy group in the 
B ring (catechol), and a C2-C3 double bond and 4-oxo function in the C ring, 
which contribute to its high antioxidant activity (van Acker et al., 1996). Further 
characteristic structural features of monoHER are the rutinose group (glucose + 
rhamnose) at the 3-O position in the C ring and the hydroxyethyl group at the 7-
O position in the A ring. 
 
 
Figure 1. Structural formula of monoHER and numbering of relevant carbon atoms. 
Preclinical studies with monoHER 
MonoHER and doxorubicin-induced cardiotoxicity  
Doxorubicin is a very effective antitumour agent, but its clinical use is limited by 
the occurrence of a cumulative dose-related cardiotoxicity, resulting in conges-
tive heart failure (Bast et al., 2007; Lipshultz et al., 2005; Singal and Iliskovic, 
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1998). Doxorubicin-induced cardiotoxicity presumably results from free radicals, 
which are produced during redox-cycling of doxorubicin (Horenstein et al., 
2000; Julicher et al., 1988; Xu et al., 2001). Because of its favorable iron chelat-
ing and radical scavenging properties (Haenen et al., 1993; van Acker et al., 
1993), monoHER was tested as a protector against doxorubicin-induced cardi-
otoxicity. 
MonoHER protected almost completely (92.7%) against doxorubicin-
induced cardiac damage in an isolated atrium model (van Acker et al., 1993). In 
mice, cardioprotection was observed when monoHER was administered as an 
intraperitoneal (i.p.) dose of 500 mg/kg five times/week in combination with a 
weekly intravenously (i.v.) dose of 4 mg/kg doxorubicin for a period of six weeks 
(van Acker et al., 1995). Cardiac damage was assessed by the changes in the 
electrocardiogram (ECG), recorded with a transmitter transplanted in the in-
traperitoneal cavity of the mice. The increase in the ST-interval of the ECG was 
used as a measure for doxorubicin-induced cardiotoxicity (Figure 2). At the end 
of the study (week 8) the ST-interval of the ECG had increased by 16.7 ± 2.7 
msec in the doxorubicin-treated mice. At the same time, the ST-interval had 
increased by only 1.7 ± 0.8 msec in the monoHER co-medicated mice (van Acker 
et al., 1995).  
 
 
Figure 2. Typical ECG trace of a mouse before (control) and after receiving 4 mg/kg doxorubicin 
with(out) 500 mg/kg monoHER for 6 weeks (van Acker et al., 2000). 
 
A later performed study showed complete protection against doxorubicin-
induced cardiac damage in mice, when monoHER was given as a single i.p. injec-
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tion (500 mg/kg) only once a week 1 hour before doxorubicin administration (4 
mg/kg, i.v.) (van Acker et al., 2000) (Figure 3). 
 
 
Figure 3. Protection by monoHER on the ST-interval lengthening of the ECG of mice treated with 
doxorubicin (van Acker et al., 2000). 
 
Since it is known that the long-term effect of doxorubicin on cardiac tissue may 
progress in time to more severe myocardial injury, resulting in cardiomyopathy 
or even chronic heart failure, it was investigated whether the cardioprotective 
effect of monoHER was maintained after a longer period of time (26 weeks). 
The cardioprotective effect lasted for a longer period of time than during the 
first 8 weeks. However, towards the end of 26 weeks of observation the cardio-
protection by monoHER was not present anymore and toxicity became compa-
rable to that in doxorubicin-treated animals (Bruynzeel et al., 2007d). Continua-
tion of weekly injections of monoHER (after 6 weeks of doxorubicin administra-
tion) for another 26 weeks even seemed to aggravate the development of dox-
orubicin-induced cardiotoxicity. This suggests that the dose and frequency of 
monoHER administration is crucial in obtaining an optimal antioxidant activity. 
Because of the relative short half-life of monoHER (about 30 minutes), the 
time interval between monoHER and doxorubicin administration (1 hour) might 
be of influence on the cardioprotective effect of monoHER, i.e. could become 
better with a shorter time interval and worse when lengthening the time inter-
val. However, data described by Bruynzeel et al. (2006) did not show a signifi-
cant change in protection against doxorubicin-induced cardiac damage when 
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the time interval between monoHER and doxorubicin changed from 10 minutes 
to 2 hours. 
Abou El Hassan et al. (2003a) investigated whether there is a pharmacoki-
netic interaction between monoHER and doxorubicin that might be involved in 
the protective effect of monoHER against doxorubicin-induced cardiotoxicity. 
The areas under the concentration-time curves (AUCs) of neither monoHER nor 
doxorubicin(ol) were affected by co-administration of the drugs. Also, no 
changes in other pharmacokinetic parameters such as initial and final half-lives, 
mean residence time, clearance and volume of distribution were observed after 
single or combined administration. This indicates that the cardioprotection 
observed in mice is not caused by a pharmacokinetic interaction between 
monoHER and doxorubicin. 
MonoHER and the antitumour activity of doxorubicin 
In order to use monoHER in clinical practice as a protector against doxorubicin-
induced cardiotoxicity, monoHER should not influence the antitumour activity 
of doxorubicin. In vitro, it was found that monoHER did not significantly influ-
ence the IC50 (which is the concentration of the drug that gives a 50% inhibition 
of cell growth) of doxorubicin in the human ovarian cancer cell lines A2780 and 
OVCAR-3, and the human breast cancer cell line MCF-7 (Table 1). Similarly, in 
vivo, monoHER did not reduce the antitumour activity of doxorubicin in A2780 
and OVCAR-3 subcutanous xenografts in nude mice (van Acker et al., 1997). 
Thus, both in vitro and in vivo, monoHER protected against the toxic effect of 
doxorubicin on cardiac cells without interfering with the cytostatic effect on 
cancer cells. 
 
Table 1. IC50 values of growth inhibition of various tumour cell lines by doxorubicin in the absence 
and presence of monoHER (van Acker et al., 1997). 
 A2780 
(10
-8
 M) 
MCF-7 
(10
-7
 M) 
OVCAR-3 
(10
-7
 M) 
Doxorubicin 2.05 ± 0.66 2.09 ± 0.75 3.28 ± 1.70 
Doxorubicin + monoHER (50 μM) 2.57 ± 1.95 1.11 ± 0.04 4.29 ± 1.95 
Doxorubicin + monoHER (100 µM) 2.00 ± 1.82 2.10 ± 0.22 5.67 ± 2.37 
Data are expressed as mean ± SD of at least three independent experiments performed in tripli-
cate. 
 
To obtain more insight in the mechanism underlying the selective protective 
effects of monoHER, it was investigated whether monoHER (1 mM) affects dox-
orubicin-induced apoptosis in neonatal rat cardiac myocytes (NeRCaMs), human 
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umbilical vein endothelial cells (HUVECs) and the ovarian cancer cell lines A2780 
and OVCAR-3. Doxorubicin-induced cell death was effectively reduced by mo-
noHER in heart, endothelial and A2780 cells. OVCAR-3 cells were highly resis-
tant to doxorubicin-induced apoptosis (Bruynzeel et al., 2007b). Experiments 
with the broad caspase-inhibitor zVAD-fmk showed that doxorubicin-induced 
apoptosis was caspase-dependent in HUVECs and A2780 cells, whereas caspase-
independent mechanisms seemed to be important in NeRCaMs. MonoHER sup-
pressed doxorubicin-dependent activation of the mitochondrial apoptotic 
pathway in normal and A2780 cells as illustrated by p53 accumulation and acti-
vation of caspase-9 and -3 cleavage (Bruynzeel et al., 2007b). These data indi-
cate that monoHER might act by suppressing the activation of molecular me-
chanisms that mediate either caspase-dependent or -independent cell death. 
However, the concentration of monoHER needed (1 mM) indicates that the in 
vitro inhibition of the antitumour effect of doxorubicin is not relevant for the 
clinical application of monoHER. 
MonoHER and doxorubicin-induced inflammation  
Some studies support the suggestion that inflammation induced by doxorubicin 
plays a role in its cardiotoxic effects (Deepa and Varalakshmi, 2006; Hecker, 
1990; Hou et al., 2005). To investigate whether doxorubicin could induce an 
inflammatory response in vitro, HUVECs were incubated with increasing con-
centrations of doxorubicin. Doxorubicin affected both the viability and prolife-
ration capacity of endothelial cells (Abou El Hassan et al., 2003c). Doxorubicin 
also increased the adhesion of neutrophils, which was accompanied by the 
overexpression of VCAM and E-selectin. MonoHER was able to protect against 
these doxorubicin-induced inflammatory effects (Abou El Hassan et al., 2003c) 
(Figure 4). 
In addition, in vivo, it was demonstrated by Bruynzeel et al. (2007a) that 
treatment with doxorubicin induces an increase of N
ε
-(carboxymethyl) lysine 
(CML) in intramyocardial arteries in mice. The induced increase in CML, which 
can be regarded as a biomarker for local endogenous stress, was found to be 
reduced by the anti-inflammatory agents, ketoprofen and dexamethasone, and 
by monoHER. These findings confirme the role of inflammation in doxorubicin-
induced cardiotoxicity and indicate that monoHER has, besides its radical scav-
enging and iron chelating properties, anti-inflammatory properties that could 
also be involved in the protection against cardiac damage. 
The anti-inflammatory effect of monoHER was also observed in a study on 
ischemia-reperfusion in mice (De Celle et al., 2004). In this study, heart ischemia 
was induced for 30 minutes by ligating the left anterior descending coronary 
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artery. Afterwards, the ligature was removed and reperfusion was allowed. 
MonoHER (500 mg/kg) was given i.p. 1 hour before ischemia. This treatment 
significantly attenuated myocardial neutrophil influx and significantly reduced 
infarct size after reperfusion (De Celle et al., 2004). 
 
 
Figure 4. Overexpression of VCAM 24 h after incubation with doxorubicin. The combined treat-
ment with monoHER prevented the concentration-dependent doxorubicin-induced overexpression 
of the adhesion molecule (Abou El Hassan et al., 2003c). 
Other pharmacological properties of monoHER 
Several other pharmacological properties of monoHER have been described. As 
an effective antioxidant, monoHER protected erythrocytes in β-thalassemic 
mice against oxidative damage involved in their premature destruction (de 
Franceschi et al., 2004). It has also been shown that monoHER has an effect on 
certain enzymes that intervene in the metabolism of mucopolysaccharides in 
human and bovine veins. The presence of monoHER (1 mg/ml) inhibited the 
enzyme β-glucuronidase extracted from human veins for 12.5% and for 70.3% 
when extracted from bovine veins, while monoHER did not significantly influ-
ence the activity of the enzyme N-acetylglucosaminidase obtained from both 
veins (Niebes and Laszt, 1971). MonoHER also affected prostaglandin synthesis 
in guinea pig lung tissue and human skin (Gosta, 1973). It has also been shown 
that monoHER has antioedematous properties in rats by inhibiting the action of 
bradykinine, histamine and carrageenin (Lecomte and Van Cauwenberge, 1974). 
Moreover, monoHER showed antithrombotic effects (Hladovec, 1977a; Mirko-
vitch, 1977), it prevented endothelial injury caused by nicotine and citrate (Hla-
dovec, 1977b; Hladovec, 1978), it increased skin capillary resistance in a rat 
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model (Gabor, 1981) and reduced microvascular permeability in frogs (Kendall 
et al., 1993). 
Metabolism, bio-availability and pharmacokinetics of monoHER 
Metabolic experiments with monoHER in the 1970s revealed that the major 
excretion route of monoHER in rats and mice is via bile by feces (Barrow and 
Griffiths, 1971; Barrow and Griffiths, 1974a; Barrow and Griffiths, 1974b; Hack-
ett and Griffiths, 1977a; Hackett and Griffiths, 1979). The minor excretion route 
was by urine. Also enterohepatic cycling has been described (Hackett and Grif-
fiths, 1977b). 
More recently, Abou El Hassan et al. (2003b) investigated the bioavailability 
of monoHER in mice after different routes of administration. Concentrations of 
monoHER in plasma and heart were measured by HPLC with electrochemical 
detection (HPLC-ECD) (Abou El Hassan et al., 2001; El Hassan et al., 2001). After 
oral administration, monoHER could not be detected in plasma, which indicates 
that monoHER has a very poor oral bioavailability (Abou El Hassan et al., 
2003b). The i.p. and subcutaneous (s.c.) bioavailabilities were about 30 and 
40%, respectively. In the same study, the pharmacokinetics of monoHER were 
determined (Table 2). Between 5 and 15 minutes after i.p. administration of 500 
mg/kg monoHER, the maximal concentration (Cmax) was reached in both plasma 
and heart tissue. Thereafter, monoHER disappeared from plasma and heart 
tissue with a half-life (t1/2) of about 30 minutes. A Cmax of about 131 μM was 
obtained in plasma, and the plasma area under the curve (AUC
∞
)
 
was 6.3 μmol 
min/ml. These values were used as end-points for a subsequent phase I study 
with monoHER. 
 
Table 2. Summary of the pharmacokinetic parameters of monoHER in plasma and heart tissue of 
mice treated with 500 mg/kg i.p.(Abou El Hassan et al., 2003b). 
Parameter Plasma Heart 
Cmax (nmol/ml or /g wet tissue) 131 35.3 
tmax (min) 5-15 5-15 
t1/2final (min) 28.5 25.7 
AUC
∞
 (µmol min/ml or /g wet tissue) 6.3 1.6 
AUC
0-120min 
(µmol min/ml or /g wet tissue) 6.1 1.6 
MRT (min) 43.6 43.0 
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Clinical studies with monoHER 
Phase I study in healthy volunteers 
Toxicity studies of monoHER in several animal models revealed neither acute 
nor chronic toxic effects nor teratogenic effects after oral administration of 
monoHER (Berte, 1974; Chesterman et al., 1973; Davies and Collins, 1973a; 
Davies and Collins, 1973b; Davies and Collins, 1973c; Hunter et al., 1973; Lu-
eschner, 1974a; Lueschner, 1974b; Lueschner, 1974c). 
To evaluate the possible side effects of monoHER and to investigate the 
pharmacokinetics of monoHER in men, a phase I clinical trial was performed 
(Willems et al., 2006). The study was performed as a single blind, randomized 
trial in healthy volunteers. MonoHER was administered as an i.v. infusion in 10 
minutes. For formulation of the drug, the required amount of monoHER was 
dissolved in 100 ml 5% dextrose for intravenous use, adjusted to pH 9.3 using 4 
M sodium hydroxide. After dissolution of the drug, the solution was readjusted 
to pH 8.4 with 1 M hydrochloric acid. The final solution was filtered through a 
0.2-µm filter. This solution was chemically stable for at least 24 hours at room 
temperature (Abou El Hassan et al., 2000). Because 10% of the registered drug 
Venoruton is monoHER and 1500 mg of Venoruton could be administered intra-
venously to patients without any side effect (Neumann et al., 1992), the starting 
dose of monoHER was 100 mg/m
2
. Dose escalation by 100% of the preceding 
dose took place after finishing each dose level until the protecting pharmacoki-
netic values for Cmax and AUC
∞
 (as observed in mice after 500 mg/kg monoHER, 
i.p.) were reached and/or serious side effects were observed. 
Up to the highest dose of 1500 mg/m
2
, monoHER was well-tolerated and no 
serious side-effects were observed. At this dose, the pharmacokinetic endpoints 
were obtained, i.e. a mean peak plasma concentration of 360 ± 69.3 μM and a 
mean AUC
∞
 of 6.8 ± 2.1 μmol min/ml. The data also showed that monoHER is 
rapidly distributed and eliminated from the plasma compartment, which corre-
sponds with a rapid uptake in and elimination from heart tissue as found in 
mice. From this phase I study, it could be concluded that 1500 mg/m
2
 of mono-
HER is a feasible and safe dose to be used in further clinical studies. 
Phase II study in cancer patients treated with doxorubicin 
Based on the promising results with monoHER observed in preclinical experi-
ments, a phase II study was performed to investigate the cardioprotective effect 
of monoHER on doxorubicin-induced cardiotoxicity in cancer patients (Bruyn-
zeel et al., 2007c). This study was performed in eight patients with metastatic 
cancer (Table 3). The patients were treated with doxorubicin preceded by a 10 
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minutes i.v. infusion of 1500 mg/m
2
 monoHER. Endomyocardial biopsies were 
evaluable in five patients. To assess cardiac damage, four of the five patients 
underwent an endomyocardial biopsy at a cumulative dose of 300 mg/m
2
 and 
one at 375 mg/m
2
 doxorubicin. Of them, three patients were treated with a 
time-interval of 1 hour between monoHER and doxorubicin, one patient with a 
time-interval of 10 minutes and one patient with a time-interval of 2 hours. 
No difference in biopsy score was found between these patients. Moreover, 
comparison of the mean biopsy score of the five patients with the mean score 
from historical data of patients who received a similar cumulative dose of dox-
orubicin, indicated that monoHER did not significantly protect against doxorubi-
cin-induced cardiotoxicity in these cancer patients. An intriguing observation in 
this clinical study was that three of the four patients diagnosed with soft tissue 
sarcomas experienced objective remissions, while the fourth had stable disease 
(Table 3). 
 
Table 3. Patient characteristics (Bruynzeel et al., 2007c). 
No. Age/sex Diagnosis Total dose of doxoru-
bicin (mg/m
2
) 
Response on 
doxorubicin 
Biopsy 
1 62/F Breast cancer 100 PD N 
2 54/F Adrenal cortical cancer 150 PD N 
3 25/M Malignant peripheral nerve 
sheet tumour 
480 PR Y 
4 64/M Malignant fibrous histiocytoma 450 PR Y 
5 55/F Breast cancer 100 PD N 
6 48/F Breast cancer 300 SD Y 
7 45/F Malignant fibrous histiocytoma 300 PR Y 
8 56/F Malignant fibrous histiocytoma 375 SD Y 
Abbreviations: PD = progressive disease; PR = partial remission; SD = stable disease. 
 
This 75% response rate is much higher than expected. The objective response 
rate obtained with doxorubicin in soft tissue sarcomas patients without prior 
chemotherapy is normally approximately 25% (Santoro et al., 1995). It is there-
fore suggestive that monoHER enhances the antitumour activity of doxorubicin 
in soft tissue sarcomas. Both the lack of clear cardioprotection and the poten-
tiation of the antitumour effect by monoHER observed in this clinical phase II 
study are in contrast with the results obtained in the earlier animal studies. 
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Aim and outline of the thesis 
As described in Chapter 1, the outcome of the clinical phase II study with mo-
noHER revealed two unexpected findings, which are in contrast to the preclini-
cal observations with monoHER: 
1. MonoHER did not significantly protect against doxorubicin-induced cardi-
otoxicity in cancer patients. 
2. It appeared that monoHER enhances the antitumour activity of doxorubicin 
in soft tissue sarcoma patients. 
To explain these unexpected clinical findings, we go back ‘from clinic to con-
cept’ in this thesis.  
First, the antioxidant properties of monoHER and its interaction with other 
antioxidants are further investigated. During their antioxidant activity, i.e., the 
scavenging of free radicals, flavonoids are converted into potentially harmful 
thiol-reactive oxidation products. Therefore, the thiol reactivity of the oxidation 
product of monoHER is studied, and the glutathione (GSH) conjugate of mono-
HER is characterized (Chapter 2). Moreover, the reactivity of the GSH-monoHER 
conjugate is investigated (Chapter 3). To protect against free radical damage 
the human body has an intricate network of antioxidants that passes over the 
reactivity from one antioxidant to another in a controlled way. The interplay of 
monoHER with this endogenous antioxidant network is investigated, and its 
position is compared with that of the well-studied flavonoid quercetin (Chapter 
4). 
The results of the clinical phase II study suggest that monoHER enhances the 
antitumour activity of doxorubicin in soft tissue sarcomas. To elucidate the mo-
lecular mechanism behind this remarkable finding, the effect of monoHER on 
the cytotoxicity of doxorubicin is studied in human soft tissue sarcoma cell lines. 
Moreover, the potential involvement of GSH depletion and nuclear factor-kB 
(NF-kB) inactivation is investigated (Chapter 5). 
In mice, monoHER has been successfully used as a protector against 
doxorubicin-induced cardiotoxicity. However, most monoHER has already been 
cleared from the body at the time that doxorubicin concentrations are still high. 
This suggests that not only the parent compound monoHER itself, but also 
monoHER metabolites could be responsible for the observed cardioprotective 
effects in mice. Therefore, the metabolism of monoHER is investigated in mice. 
Moreover, the potential meaning of the identified metabolites in the cardiopro-
tective effect of monoHER is discussed (Chapter 6). 
In humans, monoHER did not significantly protect the heart against damage 
caused by doxorubicin. To explain the different biological effects of monoHER in 
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mice and men, it is hypothesized that metabolites of monoHER that contribute 
to the observed cardioprotection in mice are not (or to a lesser extend) formed 
in men. Therefore, the metabolism of monoHER is also investigated in healthy 
volunteers and the identified metabolites are compared with those found in 
mice (Chapter 7). 
Finally, the most important findings are discussed and the future perspec-
tives are given (Chapter 8). 
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Abstract 
Flavonoids protect against oxidative stress by scavenging free radicals. During 
this protection flavonoids are oxidized. The formed oxidized flavonoids are of-
ten reactive. Consequently, protection by flavonoids can result in the formation 
of toxic products. In this study the oxidation of 7-mono-O-(β-hydroxyethyl)-
rutoside (monoHER), which is a constituent of the registered drug Venoruton,
 
was studied in the absence and presence of glutathione (GSH). MonoHER was 
oxidized by horseradish peroxidase/H2O2. Spectrophotometric and HPLC analy-
sis showed that in the presence of GSH, a monoHER-GSH conjugate was formed, 
which was identified as 2’-glutathionyl monohydroxyethylrutoside by mass 
spectrometric analysis and 
1
H NMR. Preferential formation of this glutathione 
adduct in the B ring at C2’ was confirmed by molecular quantum chemical calcu-
lations. This conjugate was also detected in the bile fluid of a healthy volunteer 
after i.v. administration of monoHER, demonstrating its formation in vivo. These 
results indicate that in the process of offering protection against free radicals, 
monoHER is converted into an oxidation product that is reactive towards thiols. 
The formation of this thiol-reactive oxidation product is potentially harmful. 
Thus, the supposed beneficial effect of monoHER as an antioxidant may be ac-
companied by the formation of products with an electrophilic, toxic potential. 
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Introduction 
Flavonoids form a class of benzo-γ-pyrone derivatives which occur naturally in 
fruits, vegetables and plant-derived beverages such as tea and wine (Nichena-
metla et al., 2006; Ren et al., 2003). They have a wide spectrum of biological 
activities (Boots et al., 2008; Choi et al., 2001; Cushnie and Lamb, 2005; Naasani 
et al., 2003; Park et al., 2007; van Acker et al., 2000a). The interest in these 
polyphenolic compounds was stimulated by the potential health benefits arising 
from their antioxidant activity, which is mainly the result of their high tendency 
to scavenge reactive oxygen species. However, during their antioxidant func-
tion, flavonoids are converted into oxidation products that take over part of the 
reactivity of the radical they have scavenged. In this way, electrophilic com-
pounds are formed that are able to damage vital cellular components (Bast and 
Haenen, 2002; Haenen and Bast, 2002). Thus, despite all their apparently useful 
antioxidant properties, flavonoids can also become toxic as a result of their 
protection (Galati et al., 2002). This holds true especially for flavonoids contain-
ing a catechol-like 3’, 4’-dihydroxy substituent pattern in their B ring (Boots et 
al., 2002).  
A well-established example of such a flavonoid is quercetin, which is one of 
the most prominent flavonoids in our diet. In the process of offering protection 
against free radicals, quercetin is chemically converted into an oxidation prod-
uct (Laughton et al., 1989; Metodiewa et al., 1999) that reacts with glutathione 
(GSH), thereby forming 2 glutathionyl adducts at position C6 and position C8 of 
the A ring (Awad et al., 2000; Boots et al., 2003; Galati et al., 2001). This high 
reactivity towards thiols can result in GSH depletion and loss of protein function 
(Boots et al., 2005). Thus, although a highly reactive species is being neutralized, 
during the same process potentially toxic products are formed, a phenomenon 
known as the quercetin paradox (Boots et al., 2007). 
The flavonoid of interest to us is the semisynthetic flavonoid 7-mono-O-(β-
hydroxyethyl)-rutoside (monoHER). MonoHER is a constituent of the registered 
drug Venoruton
 
(Haenen et al., 1993; van Acker et al., 1993), which is used in 
the treatment of chronic venous insufficiency (Petruzzellis et al., 2002). Ve-
noruton
 
(oxerutins) is a standardized mixture of the semisynthetic flavonoids 
mono-, di-, tri- and tetra-hydroxyethylrutosides. These flavonoids are obtained 
by substituting the hydroxyl groups with hydroxyethyl groups in the naturally 
occurring flavonol rutin. The most important pharmacological action of Ve-
noruton
 
is the reduction of microvascular permeability with a consequent pre-
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vention of edema (Wadworth and Faulds, 1992). In patients with chronic ve-
nous insufficiency, Venoruton improves microvascular perfusion and microcir-
culation and reduces erythrocyte aggregation. The preparation also has a possi-
ble protective effect on the vascular endothelium (Wadworth and Faulds, 
1992). MonoHER is the most powerful antioxidant of Venoruton and has in 
addition to its radical-scavenging and iron-chelating properties, an anti-
inflammatory capacity (Abou El Hassan et al., 2003; Bruynzeel et al., 2007a). 
Preclinical experiments have shown that monoHER is a potential protective 
agent against cardiotoxicity induced by the anticancer agent doxorubicin (DOX) 
(van Acker et al., 2000). Because of these promising results, clinical trials are 
being performed in patients receiving doxorubicin to study the influence of 
monoHER on DOX-induced cardiotoxicity (Bruynzeel et al., 2007b; Willems et 
al., 2006). Because the flavonoids monoHER and quercetin have many structural 
characteristics in common, it is expected that a kind of quercetin paradox also 
exists for monoHER. This may have implications for the applicability of monoH-
ER. 
The objective of this study was therefore to investigate the thiol-reactivity 
of the oxidation product of monoHER. MonoHER oxidation was induced by 
horseradish peroxidase/H2O2 and the reactivity of its oxidation product with 
glutathione was determined. The product formed in the reaction with glu-
tathione was isolated and further identified by MS and 
1
H NMR. Molecular 
quantum chemical calculations were performed to theoretically explain the 
preferential formation of the 2’-monoHER-GSH adduct. Furthermore, the bile 
fluid of a healthy volunteer who received monoHER by intravenous infusion was 
analyzed to investigate the in vivo formation of the monoHER-GSH conjugate. 
Materials and methods 
Chemicals 
MonoHER was kindly provided by Novartis Consumer Health (Nyon, Switzer-
land). Stock solutions of the drug were freshly prepared in a methanol/25 mM 
phosphate buffer (pH 3.33) mixture (4/1, v/v). Hydrogen peroxide, horseradish 
peroxidase (HRP) and reduced GSH were purchased from Sigma (St. Louis, MO, 
USA). Stock solutions of these chemicals were freshly prepared in a 145 mM 
phosphate buffer, pH 7.4. Trifluoroacetic acid (TFA) and deuterium oxide (D2O) 
were purchased from Sigma-Aldrich (Steinheim, Germany). Acetonitrile HPLC 
grade, methanol and dimethyl sulphoxide (DMSO) were obtained from Biosolve 
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(Valkenswaard, The Netherlands) and formic acid was acquired from Merck 
(Darmstadt, Germany). 
One-electron oxidation of monoHER 
The incubation mixtures contained monoHER (50 µM), HRP (1.6 nM) and H2O2 
(33 µM) in a 145 mM phosphate buffer (pH 7.4), unless noted otherwise. When 
the oxidation of monoHER was performed in the presence of GSH, the incuba-
tion mixture additionally contained 40 μM GSH. After 5 min of incubation at 
37°C, the incubation mixtures were analyzed spectrophotometrically and by 
HPLC.  
Spectrophotometric analysis 
Spectrophotometric analysis was performed with a Varian Carry 50 scan spec-
trophotometer (Varian, Mulgrave, VIC, Australia). All absorption spectra were 
recorded from 220 to 500 nm with a scan speed of 960 nm/min, using quartz 
cuvettes. The UV/Vis scans were started before and 5 min after the addition of 
HRP. 
High-performance liquid chromatography analysis 
HPLC was performed using a HP 1100 series HPLC system (Agilent Technologies, 
Palo Alto, CA, USA). Analytical separations were achieved using a Supelcosil LC 
318 column (5 µm, 25 cm x 4.6 mm) (Supelco, Bellefonte, PA, USA). The mobile 
phase consisted of water containing 0.1% (v/v) TFA with linear gradients of 5% 
acetonitrile at t = 0 to 20% acetonitrile at 5 min followed by an increase to 30% 
acetonitrile at 10 min. Finally 90% acetonitrile was used from 18 min onwards 
for 5 min. The column was reequilibrated with 5% acetonitrile for 5 min. A flow 
rate of 2 ml/min and
 
an injection volume of 20 µl were used. Detection was 
carried out with a diode array detector. The chromatograms presented are 
based on detection at 355 nm. 
Solid-phase extraction 
The GSH adduct formed upon incubation of monoHER with HRP in the presence 
of GSH was isolated by solid-phase extraction (SPE). SPE was performed with a 
Sep-Pak C18 column (WAT 051910, Waters Corp., Milford, MA, USA). The col-
umn was washed with 100% acetonitrile followed by Milli-Q water (pH 3.5). 
After application of 100 µl of the incubation mixture, the column was washed a 
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second time with Milli-Q water (pH 3.5). Next, the GSH adduct was eluted with 
water containing 5% acetonitrile. After the fraction was collected, the purity 
was checked with HPLC. Identical fractions of several extractions were pooled 
and the combined eluate was evaporated to dryness under vacuum (50°C) and 
used for further analysis by MS and 
1
H NMR analysis. 
Mass spectrometry 
A representative amount of the dried eluate was reconstituted in a 50% metha-
nol/1% formic acid (v/v) mixture and introduced into the mass spectrometer 
(MS). Mass spectrometric measurements were performed with a Finnigan LCQ 
(Thermo Electron Corp., San Jose, CA, USA) in the negative electrospray mode 
using a spray voltage of 4.5 kV and a capillary temperature of 200 °C with nitro-
gen as the sheath and auxiliary gas. 
1
H NMR spectroscopy 
1
H NMR measurements were performed in D2O at 25°C on a Varian Mercury VX 
400 MHZ NMR (Varian). 
Molecular quantum chemical calculations 
Molecular quantum chemical calculations were performed with the software 
program Spartan ’06 (Wavefunction, Irvine, CA, USA) to explain the experimen-
tal results. The calculations were carried out at the ab initio level. The Hartree-
Fock method with the 3-21G basis set was used for the equilibrium geometry 
and lowest unoccupied molecular orbital (LUMO) calculations of a simplified 
monoHER-quinone (a methyl group was used to replace the large substituents 
attached to the A7-O and C3-O). In this way, the preferential site in the monoH-
ER-quinone for nucleophilic attack by the thiol (-SH) group of glutathione was 
calculated. 
Analysis of the monoHER-glutathione adduct in the bile fluid of a healthy 
volunteer 
To evaluate the possible in vivo conjugation of monoHER with glutathione, bile 
fluid of a healthy 33-year-old male volunteer who received an intravenous mo-
noHER infusion was analyzed for the presence of the monoHER-GSH adduct. 
The volunteer signed an informed consent for the study, which had been ap-
proved by the Medical Ethical Review Committee of the University Hospital. 
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Formulation of the drug 
The monoHER infusion was formulated under aseptic conditions by the De-
partment of Pharmacy, University Hospital Gasthuisberg, Leuven, Belgium. The 
required amount of monoHER was dissolved in 100 ml 5% dextrose for intra-
venous use, adjusted to pH 9.3 using 4 M sodium hydroxide. After dissolution of 
the drug, the solution was readjusted to pH 8.4 with 1 M hydrochloric acid. The 
final solution was filtered through a 0.2-µm filter. 
Administration of the drug 
MonoHER was administered as an intravenous infusion for 15 min at a dose of 
1500 mg/m
2
. 
Bile aspiration 
Before and at 2 h after monoHER infusion, the bile fluid from the healthy volun-
teer was collected via oral intubation of a tube with a balloon, which was ma-
neuvered into the second part of the duodenum (Koek et al., 2004). The balloon 
serves to prevent mixing of gastric contents or food with duodenal contents. 
The aspiration was performed until about 10 ml was collected. The bile fluid 
was divided in portions of 1 ml and frozen at -80°C. 
Sample preparation and HPLC analysis 
Aliquots of bile fluid were mixed with twice the volume of DMSO/methanol 
(1/4, v/v). The mixture was vortexed and centrifuged (17060 g, 15 min). The 
supernatant was removed and injected onto the HPLC column. To verify the 
presence of the monoHER-GSH conjugate in the bile fluid, blank bile fluid (col-
lected before monoHER infusion) spiked with 60 µM monoHER-GSH adduct 
(synthesized as described above) was analyzed by the same procedure. 
High-performance liquid chromatography analysis of the bile samples was 
performed on a HP 1100 series HPLC system (Agilent Technologies). Analytical 
separations were achieved using a YMC-Pack ODS-AQ column (3 μm, 150 x 4.6 
mm) (YMC Europe GmbH, Dinslaken, Germany). The mobile phase consisted of 
water containing 0.1% (v/v) TFA with a linear gradient of 15% acetonitrile at t = 
0 to 30% acetonitrile at 20 min. Ninety percent acetonitrile was used from 25 
min onward for 1 min. The column was reequilibrated with 15% acetonitrile 
during 5 min. A flow rate of 1 ml/min and
 
an injection volume of 10 µl were 
used. Detection was carried out with a diode array detector. The chroma-
tograms presented are based on detection at 355 nm.  
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Results 
Spectrophotometric and HPLC analysis of the one-electron oxidation of 
monoHER 
The UV/Vis spectrum of the parent compound monoHER (50 µM) is depicted in 
Figure 1A. Two absorption maxima are observed, one at 258 nm and another 
one at 355 nm. The HPLC chromatogram of monoHER recorded at 355 nm 
shows one major peak (tR = 6.7 min) (Figure 1B). 
Figure 1. UV scans (left) and HPLC chromatograms (right) of the incubation mixture containing (A 
and B) 50 µM monoHER or (C-F) 50 µM monoHER, 1.6 nM horseradish peroxidase (HRP), and 33 
µM H2O2 in the absence (C and D) or presence (E and F) of 40 µM glutathione. The UV scans were 
recorded before and 5 min after the addition of HRP. The various incubation mixtures were in-
jected on the HPLC system 5 min after the addition of HRP. 
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Addition of the enzyme HRP to 50 μM monoHER changes the UV/Vis spectrum 
in time (Figure 1C). Four isosbestic points are observed at 249, 272, 305, and 
412 nm, suggesting the conversion of monoHER into an oxidation product. Mo-
noHER consumption is confirmed by HPLC analysis (Figure 1D). In the chroma-
togram, the peak height of monoHER (tR = 6.7 min) decreases by approximately 
67% after 5 min of incubation with HRP.  
Spectrophotometric and HPLC analysis of the glutathione adduct of monoHER 
The changes in the UV/Vis spectrum over time after addition of 40 µM GSH to 
the incubation mixture containing monoHER and HRP are shown in Figure 1E. 
Four isosbestic points are observed at 265, 280, 311, and 500 nm. These isos-
bestic points differ from the isosbestic points observed during the oxidation of 
monoHER. Comparison of the entire spectrum of the incubation mixtures with 
GSH (Figure 1E) and without GSH (Figure 1C) also indicates that the products 
formed, either in the presence or absence of GSH, are not identical. This is con-
firmed by HPLC analysis (Figure 1F). In the presence of glutathione, the peak 
height of monoHER in the chromatogram decreases and a second peak appears, 
eluting at a position different from that of the parent compound with a reten-
tion time of 5.4 min. Based on analogy with oxidized quercetin and other oxi-
dized phenolic compounds (Boots et al., 2003; Galati et al., 2001), it is tentative-
ly concluded that this second peak represents an adduct that is formed be-
tween oxidized monoHER and GSH. To confirm the formation of a monoHER-
GSH adduct, the formed product was isolated and further characterized by MS 
and 
1
H NMR. 
Mass spectrometric analysis of the monoHER-glutathione adduct 
MS analysis of the purified metabolite shows an M - 1 peak at m/z 958 (data not 
shown). This mass corresponds to the molecular weight of a mono-GSH adduct 
with monoHER. 
1
H NMR characterization of the monoHER-glutathione adduct 
To elucidate the chemical structure of the monoHER-GSH conjugate, the formed 
product was characterized by 
1
H and COSY NMR. The aromatic regions of the 
1
H 
NMR spectra of the parent compound monoHER (Figure 2A) and the monoHER-
GSH adduct (Figure 2B) measured in D2O at 25 °C are shown in Figure 2. 
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Identification of the various 
1
H NMR resonances was done on the basis of the 
1
H 
NMR chemical shifts and their splitting patterns. The doublets at 6.78 and 7.37 
ppm are assigned to H5’ and H6’, respectively. The singlets at 6.23, 6.41, and 
7.44 ppm are from H8, H6, and H2’, respectively. These results were confirmed 
by the software program ACD/HNMR Predictor (version 8.09). Comparison of 
the 
1
H NMR spectrum of the monoHER-GSH adduct to the 
1
H NMR spectral 
characteristics of the parent compound monoHER clearly reveals the loss of the 
H2’ 
1
H NMR signal. Splitting patterns of all other aromatic protons are similar to 
those of monoHER itself. On the basis of these 
1
H NMR characteristics it can be 
concluded that the GSH adduct of the oxidized flavonoid is formed in the B ring 
at C2’. This adduct can therefore be identified as 2’- glutathionyl monohydrox-
yethylrutoside (2’-monoHER-GSH adduct). The coupling of the protons was 
confirmed by COSY NMR (data not shown). 
Figure 2. Aromatic parts of the 
1
H NMR spectra of (A) the parent compound monoHER and (B) the 
metabolite formed during the incubation of monoHER with horseradish peroxidase/H2O2 in the 
presence of GSH.  
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Molecular quantum chemical calculations 
Molecular quantum chemical calculations were carried out to clarify the prefer-
ential formation of the monoHER-GSH adduct at the C2’ position in the B ring. 
After Hartree-Fock 3-21G calculations on the equilibrium geometry of the sim-
plified monoHER-quinone, a LUMO map was generated to visualize the LUMO 
distribution. Figure 3A shows that the LUMO is a π* orbital and that it is loca-
lized over the B ring and part of the C ring. Subsequently, an electron density 
surface was generated onto which the absolute value of the LUMO (|LUMO|) 
was mapped (Figure 3B). By convention, colors tending toward red indicate 
small absolute values for the LUMO (near 0), whereas colors tending toward 
blue indicate large absolute values. The |LUMO| has the highest value over the 
C2’ site at the B ring, with a maximum relative value of 0.024. The C5’ site has a 
lower maximum value of 0.017. This indicates that C2’ is the preferential site for 
nucleophilic attack, which is consistent with the experimental results.  
 
 
Figure 3. (A) LUMO map of the simplified monoHER-quinone. The LUMO is localized over the B ring 
and a part of the C ring. (B) Electron density surface of the absolute values of the LUMO for the 
monoHER-quinone. Blue indicates a high value for the orbital, and red indicates a low value. High 
values for the LUMO are seen over C2’, indicating that this is a potential site for nucleophilic at-
tack. 
Excretion of the monoHER-glutathione adduct in the bile fluid of a healthy 
volunteer 
High-performance liquid chromatographic analysis of bile fluid from a healthy 
volunteer, who received monoHER (1500 mg/m
2
) via intravenous infusion, re-
vealed the presence of the monoHER-GSH conjugate (retention time 3.1 min) 
(Figure 4A). 
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Figure 4. (A) The first part of the HPLC chromatogram of human bile fluid collected 2 h after iv 
administration of 1500 mg/m
2
 monoHER. The DAD spectrum of the peak with a retention time of 
3.1 min is shown. (B) The first part of the HPLC chromatogram of blank human bile fluid (collected 
before monoHER infusion) spiked with 60 µM synthesized monoHER-GSH conjugate. The DAD 
spectrum of the monoHER-GSH conjugate with a retention time of 3.1 min is shown. 
 
Peak identification was performed by spiking blank bile fluid (collected before 
monoHER infusion) with the previously synthesized monoHER-GSH adduct. The 
peak that consequently appears in the spiked blank bile fluid has the same re-
tention time as the peak present in the bile fluid collected after monoHER infu-
sion (Figure 4B). Also, the DAD spectrum of the peak at 3.1 min is identical to 
the characteristic spectrum of the synthesized monoHER-GSH adduct (Figure 4). 
This confirms the presence of the monoHER-GSH conjugate in the bile fluid. 
These data demonstrate, for the first time, that the monoHER-GSH adduct is 
also formed in vivo. 
Discussion 
Previous studies have documented that oxidation products of some dietary 
phenolic compounds are electrophilic and readily react with nucleophiles such 
as glutathione (Boots et al., 2003; Galati et al., 1999). A well-documented ex-
ample of such a compound is the flavonoid quercetin, which is converted into 
an oxidation product that reacts with glutathione, thereby forming two adducts 
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in which GSH is attached to the A ring, i.e., 6-GSQ and 8-GSQ (Awad et al., 2000; 
Boots et al., 2003; Galati et al., 2001). 
In this study, the oxidation product of monoHER was obtained through oxi-
dation by horseradish peroxidase/H2O2. Spectrophotometric and HPLC analysis 
of the reaction mixture confirmed the oxidation of monoHER. In the presence of 
GSH, one major product different from the oxidation product was detected. MS 
analysis showed that this product had an M - 1 peak at m/z 958. This mass cor-
responds to the molecular weight of a mono-GSH adduct with monoHER. 
1
H 
NMR analysis identified this monoHER-GSH conjugate as 2’-glutathionyl mono-
hydroxyethylrutoside, representing a glutathione adduct originating from glu-
tathione conjugation at the B ring of monoHER. Preferential formation of this 
adduct is in line with the results of the theoretical calculations for the |LUMO| 
with Spartan ’06. Moreover, conjugation of monoHER with glutathione also 
occurs in vivo, as shown by the presence of this conjugate in the bile fluid of a 
healthy volunteer after i.v. administration of monoHER. 
The semisynthetic flavonoid monoHER has many structural characteristics in 
common with quercetin. Both flavonoids belong to the subclass of the flavonols 
and contain a catechol-like 3’, 4’-dihydroxy substituent pattern in their B ring. 
This catechol moiety is most likely responsible for their potent antioxidant activ-
ity (Heijnen et al., 2002). They also contain the C2-C3 double bond and the 4-
oxo function in the C ring, which contribute to their high antioxidant function 
(Lien et al., 1999; Rice-Evans et al., 1996; van Acker et al., 1996). In contrast 
with quercetin, monoHER has a rutinose group attached to position 3 of the C 
ring, and the hydroxylgroup at position 7 of the A ring is substituted with a hy-
droxyethyl group. These small differences in their chemical structures (Figures 5 
and 6) can explain their different oxidation products and subsequent interaction 
with glutathione. MonoHER glutathionyl formation occurs at the B ring, 
whereas the glutathionyl formation with quercetin occurs at the A ring. 
After oxidation of quercetin, four tautomeric forms of the oxidation product 
can exist, one o-quinone isomer and three quinone methide isomers (Awad et 
al., 2000). Owing to the relatively high abundance of the quinone methide-type 
2 intermediate (calculations with Spartan ’06 showed that this quercetin 
tautomer had an abundance of more than 99%), glutathionyl adduct formation 
occurs at positions C6 and C8 of the quercetin A ring, i.e., 6-GSQ and 8-GSQ 
(Figure 5). 
In the chemical structure of monoHER, the C3-OH group is substituted by a 
rutinose group. This restricts the overall conjugation of the π system. Because 
the rearrangement of the proton of the 3-OH group to generate a 3-keto group 
cannot occur, the formation of quinone methide tautomers is prevented, lead-
C H A P T E R  2  
 38 
ing merely to the formation of the o-quinone isomer. Elimination of the possibil-
ities for quinone methide formation by the absence of the C3-OH group restricts 
glutathionyl adduct formation to the B ring. This is in line with our experimental 
results, which indicate that only one GSH conjugate is formed after monoHER 
oxidation in the presence of GSH, i.e., 2’-monoHER-GSH (Figure 6).  
Figure 5. Oxidation of quercetin, followed by the possible reaction of its major oxidation product 
with GSH. (A) After oxidation of quercetin, (B) four tautomeric forms of the oxidation product can 
exist, one o-quinone isomer and three quinone methide isomers. (C) Glutathionyl adduct forma-
tion occurs at positions C6 and C8 of the A ring, i.e., 6-GSQ and 8-GSQ. 
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Figure 6. Oxidation of monoHER, followed by the possible reaction of its oxidation product with 
GSH. (A) In the presence of HRP monoHER becomes oxidized and (B) the monoHER-quinone is 
formed. (C) This monoHER-quinone reacts with GSH, thereby forming the 2’-monoHER-GSH ad-
duct. 
 
Theoretically, the B ring of monoHER has two possible sites for nucleophilic 
attack of glutathione, i.e., C2’ and C5’. Molecular quantum chemical calculations 
of the LUMO with Spartan ’06 show that the LUMO is localized over the B ring 
and a part of the C ring. Comparing the relative values of the LUMO of the two 
possible sites for nucleophilic attack in the B ring of monoHER, it can be seen 
that the C2’ site has a higher |LUMO| (0.024) than the C5’ site (0.017). This 
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indicates that the C2’ atom is more susceptible to nucleophilic attack and ex-
plains the preferential formation of 2’-glutathionyl monoHER. 
For quercetin it has been found that in the process of offering protection 
against free radicals, thiol-reactive oxidation products that can cause cell dam-
age are formed (Boots et al., 2007). This phenomenon is coined as the quercetin 
paradox. When monoHER exerts its antioxidant function (i.e., scavenging free 
radicals), it is also converted into an oxidation product. This study illustrates 
that this oxidation product of monoHER shows reactivity towards thiols, which 
is evidenced by the formation of the 2’-monoHER-GSH adduct. In addition to its 
formation in vitro, this GSH conjugate is also formed in vivo, as seen by its pres-
ence in the bile fluid of a healthy volunteer who received monoHER by intrave-
nous infusion. Previous reports have indicated that GSH conjugates are formed 
in vitro (Awad et al., 2000; Boots et al., 2003; Galati et al., 2001). Attempts have 
been made by other researchers to detect the in vivo formation of conjugates 
between flavonoids and glutathione (Jones et al., 2004). To our knowledge, this 
study is the first to show that a flavonoid conjugate with glutathione really is 
formed in vivo.  
The formation of electrophilic, thiol-reactive oxidation products can have 
some implications. First of all the formed oxidation product can react with the 
thiol GSH, which will reduce GSH levels and thus the antioxidant defense. In 
addition to the reaction with GSH, it is assumed that the oxidized antioxidant is 
also prone to react with essential thiol groups of critical proteins, potentially 
resulting in the loss of protein function (Boots et al., 2005). Thus, the supposed 
beneficial effect of monoHER as an antioxidant could be eclipsed by the forma-
tion of products with an electrophilic, toxic potential. However, further research 
is necessary to determine the potential toxicological consequences. 
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Abstract 
During the scavenging of free radicals flavonoids are oxidized to electrophilic 
quinones. Glutathione (GSH) can trap these quinones, thereby forming GSH-
flavonoid adducts. The aim of the present study was to compare the stability of 
the GSH-flavonoid adduct of 7-mono-O-(β-hydroxyethyl)-rutoside (monoHER) 
with that of quercetin. It was found that GSH-quercetin reacts with the thiol N-
acetyl-L-cysteine (NAC) to form NAC-quercetin, whereas GSH-monoHER does 
not react with NAC. In addition, the adduct of the monoHER quinone with the 
dithiol dithiothreitol (DTT) is relatively stable, whereas the DTT-quercetin ad-
duct is readily converted into quercetin and DTT disulfide. These differences in 
reactivity of the thiol-flavonoid adducts demonstrate that GSH-monoHER is 
much more stable than GSH-quercetin. This difference in reactivity was corro-
borated by molecular quantum chemical calculations. Thus, although both fla-
vonoid quinones are rapidly scavenged by GSH, the advantage of monoHER is 
that it forms a stable conjugate with GSH, thereby preventing a possible spread 
of toxicity. These findings demonstrate that even structurally comparable flavo-
noids behave differently, which will be reflected in the biological effects of 
these flavonoids. 
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Introduction 
Flavonoids are a class of naturally occurring polyphenolic compounds that are 
ubiquitously present in fruits, vegetables and plant-derived beverages such as 
tea and wine (Hertog et al., 1993; Kuhnau, 1976). The interest in these sub-
stances has been stimulated by the potential health benefits arising from their 
antioxidant activity, which is mainly the result of their high tendency to sca-
venge reactive oxygen species (van Acker et al., 2000a). However, during their 
antioxidant function, flavonoids are converted into oxidation products that 
usually retain a part of the reactivity of the species they have scavenged (Bast 
and Haenen, 2002; Galati et al., 2002). In this way, electrophilic compounds are 
formed that are able to damage vital cellular compounds (O'Brien, 1991), i.e. 
the flavonoid quinone could react with protein thiols, which can lead to toxic 
effects such as increased membrane permeability (Yen et al., 2003) or altered 
functioning of enzymes that contain critical SH-groups (Kalyanaraman et al., 
1987; Moore et al., 1988). A well-established example of such a flavonoid is 
quercetin, which is one of the most prominent flavonoids in our diet. In the 
process of offering protection against free radicals, quercetin is chemically con-
verted into a quinone (Laughton et al., 1989; Metodiewa et al., 1999) that rea-
dily reacts with glutathione (GSH), thereby forming two glutathionyl adducts at 
position C6 and position C8 of the A ring (Awad et al., 2000; Boots et al., 2003; 
Galati et al., 2001).  
The flavonoid of interest to us is the semisynthetic flavonoid 7-mono-O-(β-
hydroxyethyl)-rutoside (monoHER) (Bast et al., 2007; Haenen et al., 1993; van 
Acker et al., 2000). Like quercetin, monoHER is also chemically converted into 
an electrophilic quinone as a result of scavenging reactive species (Jacobs et al., 
2009). Recently, it was shown that this monoHER quinone can be trapped by 
the thiol GSH. The binding of the quinone to GSH is considered to be a detoxifi-
cation mechanism to protect cells against harmful reactive species (Meister, 
1994; Yu, 1994). Nevertheless, previous studies with quercetin have shown that 
this reaction is reversible (Boots et al., 2005; Boots et al., 2007). Thus, the for-
mation of a GSH-quercetin conjugate might only provide a temporary protec-
tion against oxidized quercetin and even spread toxicity (Boots et al., 2005). The 
chemical structure of quercetin and monoHER, both belonging to the group of 
flavonols, are closely related. Little is known about the stability of the 2’-GSH-
monoHER adduct. This prompted us to study the reactivity of the 2’-GSH-
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monoHER with other thiols in comparison with that of the GSH adducts of 
quercetin. 
Materials and methods 
Chemicals 
7-mono-O-(β-hydroxyethyl)-rutoside (monoHER) was kindly provided by Novar-
tis Consumer Health (Nyon, Switzerland). Quercetin, reduced glutathione (GSH), 
hydrogen peroxide (H2O2), horseradish peroxidase (HRP) and dithiothreitol 
(DTT) were purchased from Sigma (St. Louis, MO, USA). N-acetyl-L-cysteine 
(NAC) was acquired from Merck (Darmstadt, Germany). Trifluoroacetic acid 
(TFA) was acquired from Sigma-Aldrich (Steinheim, Germany). Acetonitrile HPLC 
grade and methanol were obtained from Biosolve (Valkenswaard, The Nether-
lands). 2’-GSH-monoHER was synthesized as described previously (Jacobs et al., 
2009). 
Oxidation of monoHER and quercetin and subsequent formation of GSH-
monoHER and GSH-quercetin 
The procedures to oxidize monoHER and quercetin were similar to the ones 
used previously (Boots et al., 2005; Jacobs et al., 2009). Shortly, 100 µM mo-
noHER was incubated for 5 minutes at 37°C together with 1.6 nM HRP and 33 
µM H2O2 in a 145 mM phosphate buffer (pH 7.4). The GSH-monoHER adduct 
was formed by oxidizing 100 µM monoHER in the presence of 120 µM GSH. The 
NAC-monoHER adduct was formed by oxidizing 100 µM monoHER in the pres-
ence of 120 µM NAC. The DTT-monoHER adduct was formed by oxidizing 100 
µM monoHER in the presence of 120 µM DTT. The incubation mixtures were 
analyzed by high-performance liquid chromatography (HPLC). Similar experi-
mental conditions were used to oxidize quercetin and to form the subsequent 
thiol-adducts.  
Reaction of GSH-monoHER and GSH-quercetin with NAC 
The GSH-monoHER and the GSH-quercetin adducts were freshly prepared by 
oxidizing 100 μM monoHER or quercetin in the presence of 120 µM GSH, as 
described above. After 5 minutes of incubation at 37°C, the reaction was 
stopped by filtering the solution through a Sep-Pak C18 cartridge. In this way, 
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the enzyme is removed from the solution and the oxidation is stopped. Thereaf-
ter, 120 µM NAC was added to the obtained solution containing the GSH-
monoHER or GSH-quercetin adduct. After an additional 5 minutes of incubation 
at 37°C, the incubation mixture was analyzed by HPLC. 
High-performance liquid chromatography analysis 
HPLC was performed using a HP 1100 series HPLC system (Agilent Technologies, 
Palo Alto, CA, USA). Analytical separations were achieved using a Grace Smart 
RP 18 column (5 µm, 150 mm x 4.6 mm) (Grace, Deerfield, IL, USA). The mobile 
phase consisted of water containing 0.1% (v/v) TFA with linear gradients of 5% 
acetonitrile at t = 0 to 20% acetonitrile at 5 min followed by an increase to 30% 
acetonitrile at 15 min. Finally 90% acetonitrile was used from 23 min onward for 
3 min. The column was reequilibrated with 5% acetonitrile for 5 min. A flow rate 
of 2 ml/min and
 
an injection volume of 20 µl were used. Detection was carried 
out with a diode array detector (DAD). Quantification of monoHER and querce-
tin was done based on detection at 355 nm and 375 nm, respectively. 
Molecular quantum chemical calculations 
Molecular quantum chemical calculations (ab initio level) were performed with 
the software program Spartan ’06 (Wavefunction, Irvine, CA, USA) to explain 
the differences in reactivity between the GSH-monoHER and GSH-quercetin 
adducts. The activation energy for the first step of the reaction from GSH-
adduct to quinone, i.e. deprotonation of the OH-group adjacent to the position 
where GSH is bound in the flavonoid, was determined by calculating the equili-
brium geometry with the Hartree-Fock method using the 3-21G basis set. To 
omit complicated calculations because of the presence of long - hardly contri-
buting - substituents, quercetin-3,7-OMe was used instead of monoHER, and 
MeSH instead of GSH for the calculations.  
Statistics 
All experiments were performed, at least, in triplicate. Data are expressed as 
mean ± SD or as a typical example. Statistical analysis was performed using 
student’s t-test. P values ≤ 0.05 were considered statistically significant. 
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Results 
Reaction of monoHER quinone and quercetin quinone with thiols 
MonoHER and quercetin (100 μM) were incubated with a concentration of 
HRP/H2O2 that led to the oxidation of approximately 50% of both flavonoids in 5 
minutes (Figure 1). Oxidation of monoHER or quercetin in the presence of gluta-
thione (GSH) resulted in the formation of approximately 50 μM GSH-monoHER 
or GSH-quercetin. Similarly, oxidation of monoHER or quercetin in the presence 
of the thiol N-acetyl-L-cysteine (NAC) resulted in the formation of 50 μM NAC-
monoHER or NAC-quercetin.  
These results confirm that monoHER and quercetin are oxidized by 
HRP/H2O2 to quinones that readily react with thiols. Likewise, oxidation of 
monoHER in the presence of the dithiol dithiothreitol (DTT) resulted in the for-
mation of a DTT-monoHER adduct. On the other hand, when quercetin was 
oxidized in the presence of DTT, no DTT-quercetin adduct was found and also 
no net consumption of quercetin. 
 
 
Figure 1. Oxidation of the flavonoids monoHER (MH) and quercetin (Q) by horseradish peroxidase 
(HRP) and H2O2 without or with the thiols glutathione (GSH), N-acetyl-L-cysteine (NAC) or dithio-
threitol (DTT). The composition of the incubation mixtures was: (A) 100 µM monoHER or 
quercetin, (B) 100 µM monoHER or quercetin, 1.6 nM HRP and 33 µM H2O2, (C) 100 µM monoHER 
or quercetin, 1.6 nM HRP, 33 µM H2O2 and 120 µM GSH, (D) 100 µM monoHER or quercetin, 1.6 
nM HRP, 33 µM H2O2 and 120 µM NAC and (E) 100 µM monoHER or quercetin, 1.6 nM HRP, 33 µM 
H2O2 and 120 µM DTT. The incubation mixtures were incubated for 5 minutes at 37°C. The remain-
ing flavonoid and the formed thiol-flavonoid adducts were quantified by HPLC. Experiments were
performed at least in triplicate and data are shown as mean ± SD. 
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Reaction of GSH-monoHER and GSH-quercetin with NAC 
Subsequently, GSH-monoHER and GSH-quercetin were incubated with the thiol 
NAC for 5 minutes. As shown in Figure 2A, GSH-monoHER did not react with 
NAC, i.e., the concentration of the GSH-monoHER adduct remained the same 
and no NAC-monoHER was formed within the 5 minutes of incubation. In con-
trast, GSH-quercetin did react with NAC: the major part of the GSH-quercetin 
adduct was gradually converted into NAC-quercetin (Figure 2B).  
Figure 2. Reaction of the GSH-flavonoid (50 μM) with NAC (120 μM). (A) With GSH-monoHER, 
there is no consumption of GSH-monoHER ( ) over time and no NAC-monoHER ( ) is formed. (B) 
With GSH-quercetin, NAC-quercetin ( ) is formed and the concentration of GSH-quercetin ( ) 
decreases in time. Experiments were performed at least in triplicate and data are shown as mean ± 
SD. 
Discussion 
The flavonoids monoHER and quercetin are converted into quinones when they 
scavenge free radicals. The results of our study confirm that both the monoHER 
quinone and the quercetin quinone react with GSH to form the 2’-GSH-
monoHER and 6- or 8-GSH-quercetin adducts, respectively (Boots et al., 2003; 
Jacobs et al., 2009). The flavonoid quinones also readily react with other thiols 
(Jacobs et al., 2010), as also illustrated in the present study with NAC as a thiol. 
The reaction of thiols with the flavonoid quinones is depicted in Figure 3. It 
is a Michael addition in which the thiol acts as a nucleophile. In this reaction, a 
Meisenheimer complex (Figure 3c) is formed as an intermediate that eventually, 
via deprotonation and subsequent protonation, forms the resulting thiol-
flavonoid adduct (Figure 3e). 
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Figure 3. Reaction of the monoHER quinone (A) and the quercetin quinone (B) with monothiols 
(GSH or NAC). This reaction is a Michael addition. In the case of the monoHER quinone, first the 
nucleophilic thiolate (RS
-
) attacks the monoHER quinone at the 2’-position in the B ring (a). By 
protonation a Meisenheimer complex is formed (c). After deprotonation (d) and subsequent pro-
tonation the resulting thiol-flavonoid adduct is formed (e). In the case of the quercetin quinone, 
the Michael addition starts with the nucleophilic attack of the thiolate (RS
-
) at the 6- or 8-position 
in the A ring of the quercetin quinone. The subsequent reactions are comparable to those of 
monoHER. 
 
As expected the monoHER quinone also reacts with the dithiol DTT to form a 
DTT-monoHER adduct (Figure 1). Intriguingly, it seems as if the quercetin qui-
none does not react with DTT, i.e. no DTT-quercetin adduct formation and no 
net consumption of quercetin were observed when quercetin was oxidized in 
the presence of DTT. Considering the reactivity of the quercetin quinone to-
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wards thiols, the quercetin quinone has to react with DTT (e.g. in analogy with 
GSH and NAC, Figure 3A) to form a DTT-quercetin adduct. In contrast to GSH or 
NAC, DTT contains two thiol groups that easily form an intramolecular disulfide. 
That no DTT-quercetin adduct was detected in our experiments has to be due to 
the presence of these two thiol groups. As depicted in Figure 4, one of the thiol 
groups attacks the quercetin quinone to form DTT-quercetin. In a second reac-
tion step, due to the presence of the free intramolecular SH-group in the DTT 
moiety, which has a high tendency to form a six-membered ring with an internal 
disulfide bond, the DTT-quercetin adduct is rapidly converted into quercetin 
and DTT disulfide. This rapid conversion of the DTT-quercetin adduct explains 
why, in contrast to DTT-monoHER, this adduct was not found when quercetin 
was oxidized in the presence of DTT. This reaction is comparable to the reac-
tions of DTT with disulfides and other compounds that also proceed relatively 
fast with a DTT adduct as an intermediate (Haenen et al., 1990). 
 
Figure 4. Conversion of DTT-quercetin (a) into quercetin and DTT-disulfide (d). The reaction starts 
with tautomerization by deprotonation of the 7-OH group of DTT-quercetin and the subsequent 
protonation of C8 (b). This results in the formation of a Meisenheimer complex (c), which ulti-
mately results in the formation of quercetin and DTT disulfide (d). 
 
In the reaction of thiols with the quercetin quinone, the thiol, and most proba-
bly also one of the thiol groups of DTT, is attached to the 6- or 8-position in the 
flavonoid A ring, whereas with monoHER the thiol is attached to the 2’-position 
in the B ring (Boots et al., 2003; Jacobs et al., 2009) (Figure 3). The conversion of 
DTT-quercetin into quercetin and DTT disulfide starts with the deprotonation of 
the 7-OH group in DTT-quercetin (Figure 4b). This is the group adjacent to the 
thiol-flavonoid bond. In the case of DTT-monoHER this would be the 3’-OH (Fig-
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ure 3d). Quantum molecular calculations show that deprotonation of the 3’-OH 
of RSH-monoHER needs more activation energy (ca. 100 kJ/mol more) than 
deprotonation of the 7-OH of RSH-quercetin. This explains why the DTT-
monoHER adduct is, unlike DTT-quercetin, not rapidly converted into monoHER 
and DTT disulfide. 
A similar intriguing finding was that the GSH-quercetin adduct reacts with 
other thiols (e.g. NAC) whereas the GSH-monoHER adduct does not (Figure 2). 
The formation of the NAC-flavonoid adduct from the GSH-flavonoid adduct 
includes two sequential steps: (i) the reverse of the reaction depicted in Figure 
3, i.e. the conversion of the GSH-flavonoid into the flavonoid quinone and GSH, 
and (ii) the reaction of the flavonoid quinone with NAC. In the first step, the OH 
group in the GSH-flavonoid adduct adjacent to the position where GSH is 
chemically bound has to be deprotonated first (Figure 3e  d). The deprotona-
tion enables the formation of the Meisenheimer complex (Figure 3c) and ulti-
mately the formation of the quinone and GSH. This deprotonation is similar to 
the deprotonation of the DTT-flavonoid adduct (Figure 4a  b) and requires 
more activation energy (ca. 100 kJ/mol) in GSH-monoHER than in GSH-
quercetin. This explains why GSH-monoHER, in contrast to GSH-quercetin, is not 
converted into NAC-monoHER. 
As explained above, to convert the GSH-flavonoid adduct into the NAC-
flavonoid adduct, the flavonoid quinone has to be formed first. In the most 
abundant tautomer of the quercetin quinone (Figure 3B, a), the distance be-
tween the electron deficient carbonyl centers is maximal within the flavonoid 
backbone. In the ortho-quinone of monoHER two carbonyls are adjacent (Figure 
3A, a), which is energetically unfavorable compared to the larger distance be-
tween these groups in the quercetin quinone (Jacobs et al., 2010). This might 
also contribute to why the GSH-quercetin adduct is readily converted into GSH 
and the quercetin quinone that subsequently reacts with NAC, whereas the 
GSH-monoHER adduct is not. 
Both the monoHER quinone and the quercetin quinone readily react with 
thiols, also when they are formed in a biological system (Jacobs et al., 2010) 
(Figure 5). In the case of the quercetin quinone, this reaction has shown to be 
reversible. This indicates that after the quercetin quinone has reacted with GSH, 
the quinone may still react with other thiols, as demonstrated by the formation 
of the NAC-quercetin adduct. In tissues with GSH in abundance, like the liver, 
this is not likely to cause any problem because the quinone will be trapped 
again by GSH. However, in e.g. blood plasma, where GSH is practically absent, 
or when GSH has been depleted, the quercetin quinone might bind to essential 
thiols of vital proteins. This can cause toxicity such as increased membrane 
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permeability (Yen et al., 2003) or impaired functioning of enzymes that depend 
on a critical thiol-group (Kalyanaraman et al., 1987; Moore et al., 1988). In this 
way, the GSH-quercetin adduct might serve as a transport or storage of oxidized 
quercetin, and even spread toxicity (Boots et al., 2005).  
 
Figure 5. Schematic overview depicting the essential difference between quercetin and monoHER. 
When monoHER and quercetin protect against oxidative stress by scavenging free radicals, both 
flavonoids are oxidized, thereby forming flavonoid quinones. Both the monoHER quinone and the 
quercetin quinone can react with GSH to form a GSH-monoHER and a GSH-quercetin adduct, 
respectively. The GSH-quercetin adduct can be converted back into the quercetin quinone and 
GSH. Thereby, especially in tissue where GSH levels are low, the quercetin quinone might react 
with other thiols groups, such as protein thiols, which will cause toxicity. The GSH-monoHER ad-
duct is more stable than the GSH-quercetin adduct. This means that once the monoHER quinone is 
bound to GSH it will not be transferred to other thiols, thereby preventing spread of toxicity. 
Moreover, it has been shown that the monoHER quinone, in contrast to the quercetin quinone, 
reacts with the antioxidant ascorbate rather than with thiols. 
 
The GSH-monoHER adduct, in contrast to the GSH-quercetin adduct, is relatively 
stable. As shown in the present study, once the monoHER quinone is scavenged 
by GSH, it will not readily react with other thiols. Moreover, this GSH-monoHER 
adduct is highly water-soluble and is expected to be excreted by the body. The 
GSH-monoHER adduct has been detected in vivo in the bile fluid of healthy vo-
lunteers (Jacobs et al., 2009). In this way, the toxic oxidation products are elimi-
nated and there will be no spread of toxicity. In blood plasma, the monoHER 
quinone might, similarly to the quercetin quinone, also react with protein thiols 
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and cause toxicity. However, the monoHER quinone, in contrast to the querce-
tin quinone, reacts with ascorbate rather than with protein thiols (Jacobs et al., 
2010). In this way, the reactivity of the radicals becomes completely neutra-
lized.  
In general, flavonoids are treated as a group of antioxidants that have simi-
lar interactions with biological systems. Our study shows that GSH-monoHER is 
stable, whereas GSH-quercetin readily reacts with other thiols. This demon-
strates that even structurally comparable flavonoids behave differently. This 
should be considered in evaluating the biological effects of flavonoids. 
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Abstract 
Antioxidants can scavenge highly reactive radicals. As a result the antioxidants 
are converted into oxidation products that might cause damage to vital cellular 
components. To prevent this damage, the human body possesses an intricate 
network of antioxidants that pass over the reactivity from one antioxidant to 
another in a controlled way. The aim of the present study was to investigate 
how the semi-synthetic flavonoid 7-mono-O-(β-hydroxyethyl)-rutoside (mo-
noHER), a potential protective agent against doxorubicin-induced cardiotoxicity, 
fits into this antioxidant network. This position was compared with that of the 
well-known flavonoid quercetin. The present study shows that the oxidation 
products of both monoHER and quercetin are reactive towards thiol groups of 
both GSH and proteins. However, in human blood plasma, oxidized quercetin 
easily reacts with protein thiols, whereas oxidized monoHER does not react with 
plasma protein thiols. Our results indicate that this can be explained by the 
presence of ascorbate in plasma; ascorbate is able to reduce oxidized monoHER 
to the parent compound monoHER before oxidized monoHER can react with 
thiols. This is a major difference with oxidized quercetin that preferentially 
reacts with thiols rather than ascorbate. The difference in selectivity between 
monoHER and quercetin originates from an intrinsic difference in the chemical 
nature of their oxidation products, which was corroborated by molecular quan-
tum chemical calculations. These findings point towards an essential difference 
between structurally closely related flavonoids in their interplay with the endo-
genous antioxidant network. The advantage of monoHER is that it can safely 
channel the reactivity of radicals into the antioxidant network where the reac-
tivity is completely neutralized. 
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Introduction 
The human body is endowed with a wide range of antioxidants to protect cells 
from damage induced by free radicals and other reactive species. Glutathione 
(GSH) is one of the most important endogenous hydrophilic antioxidants 
(Meister, 1994a). It is synthesized in many different cell types from its constitut-
ing amino acids glutamic acid, cysteine and glycine, and is therefore not re-
quired in the human diet (Meister, 1994a). The actual antioxidant property of 
GSH is attributable to the thiol group that is present in its cysteine moiety. As an 
effective nucleophile, GSH also plays an important role in the protection against 
electrophilic compounds (Yu, 1994).  
Like GSH, ascorbic acid (vitamin C) is also an important hydrophilic antioxi-
dant. In contrast to GSH, ascorbic acid cannot be synthesized by humans and, as 
a consequence, is required in the human diet (Meister, 1994b). It directly scav-
enges O2˙ˉ and ˙OH and various other radicals.  
Phenolic antioxidants comprise α-tocopherol (the most active form of vita-
min E) and flavonoids. Like ascorbic acid and most other vitamins, α-tocopherol 
has to be obtained exclusively from the diet. It is the major
 
lipid-soluble lipopro-
tein antioxidant (Niki, 1987). α-Tocopherol is localized in biomembranes and 
functions as an efficient inhibitor of lipid peroxidation. Flavonoids, on the other 
hand, are not essential nutrients but they form an integral part of the human 
diet as they are found in fruits, vegetables, nuts and plant-derived beverages 
such as tea and wine (Hertog et al., 1993; Kuhnau, 1976). They have a wide 
range of biological activities (Landis-Piwowar and Dou, 2008; Liu et al., 2010; 
Rathee et al., 2009), but are most commonly known for their antioxidant activ-
ity. Quercetin is one of the most frequently studied dietary flavonoids (Formica 
and Regelson, 1995; Hertog et al., 1993). It can scavenge highly reactive species, 
an activity that is implicated in its health benefits (Amic et al., 2007; Boots et al., 
2008).  
The flavonoid of interest to us, that closely resembles the chemical struc-
ture of quercetin, is the semi-synthetic flavonoid 7-mono-O-(β-hydroxyethyl)-
rutoside (monoHER). MonoHER is the most powerful antioxidant constituent of 
the registered drug Venoruton® (Haenen et al., 1993), which is used in the 
treatment of chronic venous insufficiency (Petruzzellis et al., 2002). In vitro 
screening has shown that monoHER is the most potent protector against cardio-
toxicity induced by the anticancer agent doxorubicin within a series of flavon-
oids (Haenen et al., 1993). Preclinical experiments have confirmed that mono-
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HER is indeed a potential protective agent against doxorubicin-induced cardio-
toxicity (van Acker et al., 2000; van Acker et al., 1995). Because of these promis-
ing results, clinical trials are being performed to study the protection of intrave-
nously administered monoHER against doxorubicin-induced cardiotoxicity in 
cancer patients (Bruynzeel et al., 2007; Willems et al., 2006). The antioxidant 
activity of monoHER is supposed to be involved in its protection. Because of its 
excellent radical scavenging properties monoHER can effectively protect the 
heart against free radicals produced by doxorubicin. 
During the scavenging of highly reactive species, antioxidants donate an 
electron or a hydrogen atom to the radical involved, thereby converting the 
radical into a relatively stable non-radical. In this way the reactivity of the radi-
cal is annihilated. However, in this reaction the antioxidant itself is converted 
into an oxidation product that takes over part of the reactivity of the radical. 
This oxidized antioxidant might cause damage to vital cellular components (Bast 
and Haenen, 2002). For example, when α-tocopherol scavenges free radicals it 
is oxidized to produce the corresponding tocopheroxyl radicals (Mukai et al., 
1991). These radicals can recombine with other radicals, such as peroxyl radi-
cals, thereby neutralizing them (Upston et al., 1999). However, when these 
tocopheroxyl radicals cannot be eliminated, lipid peroxidation is aggravated, a 
phenomenon referred to as tocopherol-mediated peroxidation (Bowry et al., 
1992; Upston et al., 1999). 
To prevent damage by reactive oxidation products of antioxidants, the hu-
man body has a refined network of antioxidants that pass over the reactivity 
from one antioxidant to another in a controlled way, thereby gradually dimin-
ishing the reactivity of the radical and recycling the antioxidants. In this way, it 
has been shown that ascorbate can regenerate α-tocopherol from tocopheroxyl 
radicals, thereby preventing tocopherol-mediated peroxidation (Mukai et al., 
1991; Niki, 1987; Packer et al., 1979). This illustrates that antioxidants act in 
synergy to annihilate radicals. Besides preventing damage induced by harmful 
oxidation products, regeneration is important because it restores the antioxi-
dant network.  
The regeneration of α-tocopherol by ascorbate is well documented, how-
ever, not much is known on the regeneration of flavonoids. When quercetin 
protects against free radicals, thiol-reactive oxidation products of quercetin are 
formed that can cause damage to vital cellular components, a phenomenon 
known as the quercetin paradox (Boots et al., 2007). Recently it was found that 
the oxidation product of monoHER is also reactive towards thiols (Jacobs et al., 
2009). This might have implications for the applicability of monoHER. However, 
T H E  A N T I O X I D A N T  N E T W O R K  
 61 
as mentioned above, antioxidants do not act in isolation to protect against oxi-
dative damage.  
The aim of the present study was to determine how monoHER fits into the 
antioxidant network and to get insight in the regeneration of flavonoids. Par-
ticularly, the reactivity of oxidized monoHER towards thiols and ascorbate was 
investigated. In addition a comparison with quercetin was made. 
Materials and methods 
Ethics Statement 
For the study spare, anonymised human blood plasma obtained from the Aca-
demic Hospital Maastricht was used according to the procedure approved by 
the medical ethical review board of the hospital. 
Chemicals 
7-mono-O-(β-hydroxyethyl)-rutoside (monoHER) was kindly provided by Novar-
tis Consumer Health (Nyon, Switzerland). Stock solutions of the drug were 
freshly prepared in a methanol/25 mM phosphate buffer (pH 3.33) mixture 
(4/1, v/v). Quercetin was purchased from Sigma (St. Louis, MO, USA) and stock 
solutions were freshly prepared in methanol. Bovine serum albumin (BSA), re-
duced glutathione (GSH), hydrogen peroxide (H2O2), horseradish peroxidase 
(HRP), L-ascorbic acid (vitamin C) and 5,5´-dithiobis-(2-nitrobenzoic acid) (DTNB) 
were also purchased from Sigma (St. Louis, MO, USA). Trifluoroacetic acid (TFA) 
was acquired from Sigma-Aldrich (Steinheim, Germany). Acetonitrile HPLC 
grade and methanol were obtained from Biosolve (Valkenswaard, The Nether-
lands). 2’-GSH-monoHER was synthesized as described previously (Jacobs et al., 
2009). 
Oxidation of monoHER 
MonoHER was oxidized as described before (Jacobs et al., 2009). Shortly, 50 µM 
monoHER was incubated for 5 minutes at 37 °C together with 1.6 nM HRP and 
33 µM H2O2 in a 145 mM phosphate buffer (pH 7.4). The GSH-monoHER adduct 
was formed by oxidizing 50 µM monoHER in the presence of 40 µM GSH. To 
investigate the influence of ascorbate on the oxidation of monoHER and on the 
formation of the GSH-monoHER adduct, ascorbate (final concentration of 40 
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µM, unless noted otherwise) was added to the incubation mixtures. The reac-
tions were monitored spectrophotometrically and by HPLC. MonoHER con-
sumption was determined at 355 nm, ascorbate consumption at 270 nm.  
Spectrophotometric analysis 
Spectrophotometric analysis was performed with a Varian Carry 50 spectropho-
tometer (Varian, Mulgrave, VIC, Australia). All absorption spectra were record-
ed from 220 to 500 nm with a scan speed of 960 nm/min, using quartz cuvettes. 
The UV/Vis scans were started 30, 150 and 300 seconds after the addition of 
HRP. 
High-performance liquid chromatography analysis 
High-performance liquid chromatography (HPLC) was performed using a HP 
1100 series HPLC system (Agilent Technologies, Palo Alto, CA, USA). Analytical 
separations were achieved using a Supelcosil LC 318 column (5 µm, 25 cm x 4.6 
mm) (Supelco, Bellefonte, PA, USA). The mobile phase consisted of water con-
taining 0.1% (v/v) TFA with linear gradients of 5% acetonitrile at t = 0 to 20% 
acetonitrile at 5 min followed by an increase to 30% acetonitrile at 10 min. Fi-
nally 90% acetonitrile was used from 18 min onward for 5 min. The column was 
reequilibrated with 5% acetonitrile for 5 min. A flow rate of 2 ml/min and
 
an 
injection volume of 20 µl were used. Detection was carried out with a diode 
array detector (DAD). The chromatograms presented are based on detection at 
355 nm (absorption maximum of monoHER). 
Measurement of thiol reactivity 
To determine the thiol reactivity of oxidized monoHER and quercetin, free SH-
groups were measured using the DTNB [5, 5´-dithiobis-(2-nitrobenzoic acid)] 
assay. The incubation mixtures contained 50 µM monoHER, 1.6 nM HRP, 33 µM 
H2O2 and 40 µM GSH (or 400 μM BSA) in a 145 mM phosphate buffer (pH 7.4). 
When the oxidation was performed in the presence of ascorbate, the incuba-
tion mixture additionally contained 40 µM of ascorbate. After 0 or 5 minutes of 
incubation at 37 °C, thiol content was measured by adding DTNB (final concen-
tration of 0.6 mM) to the incubation mixtures. The formation of TNB was meas-
ured spectrophotometrically at 412 nm. Similar experiments with 50 µM mo-
noHER were performed in human blood plasma to determine the reactivity 
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towards plasma protein thiols. Identical experimental conditions were used to 
determine thiol reactivity of oxidized quercetin.  
Molecular quantum chemical calculations 
Molecular quantum chemical calculations (ab initio level) were performed with the 
software program Spartan ’06 (Wavefunction, Irvine, CA, USA) to corroborate the 
experimental results. The Møller Plesset, RI-MP2 with the 6-31G* basis set was 
used to calculate the relative abundance of the tautomers of oxidized querce-
tin. The Hartree-Fock method with the 3-21G basis set was used for calculating the 
equilibrium geometry and the energies of the lowest unoccupied molecular orbital 
(LUMO) of the quercetin quinone methide and a simplified monoHER quinone (the 
rutin group at C3-O and the ethoxygroup at C7-O were replaced by methyl groups) 
and the highest occupied molecular orbital (HOMO) of GSH and ascorbate, unless 
depicted otherwise. In addition, a LUMO map for the monoHER quinone and the 
quercetin quinone methide were generated to get a visual on the LUMO distribu-
tion. 
Statistics 
All experiments were performed, at least, in triplicate. Data are expressed as 
mean ± SD or as a typical example. Statistical analysis was performed using 
student’s t-test. P values ≤ 0.05 were considered statistically significant. 
Results 
GSH reacts with oxidized monoHER to form 2’-GSH-monoHER 
UV and HPLC analysis (Figure 1A and Figure 2A) show that oxidation of 50 µM 
monoHER by HRP/H2O2 leads to the consumption of monoHER at a rate of 5.5 ± 
0.4 μM/min (Figure 3). In the presence of 40 μM GSH, all the oxidized monoHER 
is recovered as 2’-GSH-monoHER at a rate of 5.5 ± 0.3 µM/min (Figure 3). This is 
concluded from the appearance of the characteristic UV spectrum of 2’-GSH-
monoHER (Figure 1B) and HPLC analysis of the incubation mixture (Figure 2B). 
In the HPLC chromatogram a second peak emerges, eluting at a position iden-
tical to that of the synthesized 2’-GSH-monoHER adduct. These data demon-
strate that the monoHER quinone is formed as a primary oxidation product and 
that this oxidation product forms an adduct with GSH. 
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Ascorbate reduces oxidized monoHER to monoHER 
As shown by UV and HPLC analysis, addition of 40 μM ascorbate to the incuba-
tion mixture containing monoHER and HRP/H2O2 prevents monoHER consump-
tion (Figure 1C and Figure 2C). At the same time the ascorbate concentration 
decreases, as seen in the spectrum as a decrease of the absorption at 270 nm. 
When monoHER is omitted from the incubation mixture, there is no detectable 
ascorbate consumption. These findings suggest that monoHER is regenerated 
from its oxidation product by ascorbate.  
The average rate of ascorbate consumption in the presence of monoHER 
(4.3 ± 0.3 μM/min) is 23% less than monoHER consumption in the absence of 
ascorbate (5.5 ± 0.4 μM/min) (Figure 3). Addition of more ascorbate (final con-
centration of 100 μM) to the incubation mixture reduces the ascorbate con-
sumption to 1.5 ± 0.1 μM/min, 72% less than monoHER consumption without 
ascorbate. This indicates that the enzyme HRP is also partially inhibited by 
ascorbate, as has been shown previously (Boots et al., 2003). The extent of 
inhibition depends on the ascorbate concentration.  
 
Figure 1. Spectrophotometrical analyses. Spectrophotometrical analysis of the incubation mixture 
containing (A) 50 µM monoHER, 1.6 nM horseradish peroxidase (HRP) and 33 µM H2O2. The same 
experiment was carried out in (B) the presence of 40 µM GSH, (C) 40 µM ascorbate and (D) both 40 
µM GSH and 40 µM ascorbate. The UV/Vis scans were recorded 30, 150 and 300 seconds after the 
addition of HRP. A typical example is shown. 
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Figure 2. HPLC analyses. HPLC analysis of the incubation mixture containing (A) 50 µM monoHER, 
1.6 nM horseradish peroxidase (HRP) and 33 µM H2O2. The same experiment was carried out in (B) 
the presence of 40 µM GSH, (C) 40 µM ascorbate and (D) both 40 µM GSH and 40 µM ascorbate. 
The different incubation mixtures were injected on the HPLC system 5 minutes after the addition 
of HRP. A typical example is shown. The retention time of monoHER is 6.7 min and that of 2’-GSH-
monoHER is 5.4 min. The initial peak height of monoHER before oxidation was 88 mAU, corre-
sponding to a concentration of 50 µM. After 5 minutes of oxidation the monoHER concentrations 
in the incubation mixtures A, B, C and D were 22.5 µM, 22.5 µM, 50 µM and 43.5 µM, respectively. 
Competition between GSH and ascorbate for oxidized monoHER 
To investigate the competition between GSH and ascorbate, monoHER was 
oxidized in the presence of both compounds (Figure 1D and Figure 2D). Com-
parison of the rate of 2’-GSH-monoHER formation (1.3 ± 0.1 μM/min) and the 
rate of ascorbate consumption (3.0 ± 0.3 μM/min) (Figure 3) indicates that oxi-
dized monoHER reacts two to three times faster with ascorbate than with GSH. 
These results are in contrast with those found for quercetin. In a comparable 
competition experiment with quercetin it was found that oxidized quercetin 
predominantly reacts with GSH (Boots et al., 2003).  
As shown in Figure 4A, both oxidized monoHER and oxidized quercetin, 
produced in situ by HRP/H2O2-mediated oxidation, decrease the thiol content of 
the incubation mixture containing 40 µM GSH to approximately 50% in 5 min-
utes. The presence of ascorbate (40 µM) does not affect the consumption of 
thiols by oxidized quercetin (Figure 4B). In contrast, ascorbate significantly de-
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creases the thiol consumption induced by oxidized monoHER (Figure 4B). This 
confirms that oxidized monoHER preferentially reacts with ascorbate, whereas 
oxidized quercetin preferentially reacts with GSH. 
 
 
Figure 3. MonoHER and ascorbate consumption rates. Consumption of monoHER and ascorbate in 
the incubation mixtures containing 50 μM monoHER, 1.6 nM HRP and 33 μM H2O2 in the presence 
of either 40 μM GSH, 40 μM ascorbate or both 40 μM GSH and 40 μM ascorbate. The incubation 
time was 5 minutes. All measurements were carried out in triplicate and data are expressed as 
mean ± SD. 
Competition between protein thiols and ascorbate for oxidized monoHER and 
oxidized quercetin 
Next, monoHER and quercetin were oxidized in human blood plasma. In human 
blood plasma GSH is practically absent and ascorbate concentrations are 40-60 
µM (Brubacher et al., 2000). The generation of oxidized quercetin decreases the 
thiol content of plasma, i.e. protein thiols, by approximately 40% (Figure 4C). In 
contrast, the generation of oxidized monoHER has no effect on the thiol content 
of human blood plasma (Figure 4C). An additional experiment shows that oxi-
dized monoHER is able to react with the thiol group of albumin, which is the 
most abundant plasma protein (Figure 4D). Ascorbate is able to prevent the 
reaction of oxidized monoHER with albumin (Figure 4D). 
These results point towards an essential difference between monoHER and 
quercetin, i.e. oxidized monoHER rather reacts with ascorbate than with protein 
thiols, while oxidized quercetin preferentially reacts with protein thiols.  
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Figure 4. Reactivity of oxidized monoHER and oxidized quercetin towards thiols. Thiol content of 
the incubation mixture containing 50 μM monoHER or quercetin, 1.6 nM HRP and 33 μM H2O2 in 
the presence of either (A) 40 μM GSH, (B) both 40 μM GSH and 40 μM ascorbate, (C) human blood 
plasma or (D) 400 μM albumin (BSA) (with or without 40 μM ascorbate). The thiol content of the 
different incubation mixtures was measured 5 minutes after the addition of HRP. All measure-
ments were carried out in triplicate and data are expressed as mean ± SD. *P<0.05 compared to 
control. 
Explanation of the difference in reactivity between oxidized monoHER and 
oxidized quercetin 
Molecular quantum chemical calculations show that the tautomer depicted in 
Figure 5A, a quinone methide, represents more than 99% of oxidized quercetin. 
In oxidized monoHER only the ortho-quinone, illustrated in Figure 5B, can be 
formed. Generation of a LUMO map of oxidized monoHER and oxidized querce-
tin shows that the LUMO of oxidized monoHER is restricted to the B ring and 
part of the C ring, while the LUMO of oxidized quercetin is delocalized over all 
the phenolic rings (Figure 5). The LUMO of the monoHER ortho-quinone and the 
quercetin quinone methide are 42.6 kJ/mol and 0.0605 kJ/mol, respectively, 
showing that oxidized monoHER is a harder electrophile than oxidized querce-
tin. The HOMO of ascorbate and GSH are -394 kJ/mol and -1.35 kJ/mol, respec-
tively, showing that ascorbate is a harder nucleophile than GSH. According to 
Pearson’s HSAB concept (Pearson, 1963), hard electrophiles react faster and 
form stronger bonds with hard nucleophiles, explaining the preferential reac-
tion of oxidized monoHER with ascorbate over thiols.  
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Figure 5. LUMO delocalization maps. LUMO delocalization map of (A) oxidized quercetin and (B) 
oxidized monoHER. In oxidized monoHER, the rutin group at C3
were replaced by methyl groups and for quercetin, the most abundant tautomer (>99%) was used. 
The LUMO of oxidized monoHER is localized in the B ring and part of the C ring, while the LUMO of 
oxidized quercetin is distributed over all the phenolic rings (rings A, C and B).
Discussion 
Paradoxically, free radical scavenging antioxidants are chemically converted
potentially harmful oxidation products when they protect against free radicals 
(Bast et al., 1991). These oxidation products usually retain a part of the reactiv
ty of the species they have scavenged, and might therefore cause damage t
vital cellular targets (Bast and Haenen, 2002; Haenen and Bast, 2002)
tect cells against this damage the human body h
the reactivity is transferred from one antioxidant to another, thereby gradually 
diminishing the reactivity (Bast et al.
The aim of the present study was to investigate how monoHER fits into this 
endogenous antioxidant network. The interaction of monoHER with the ne
work was compared with that of quercetin, which chemically closely resembles 
monoHER. The results of this study show that oxidized monoHER is reduced by 
ascorbate to recycle the parent compound monoHER, while oxid
reacts with GSH to form a GSH-conjugate. The reactions of oxidized quercetin 
with ascorbate and GSH are similar to those of oxidized monoHER 
2003). However, as shown in the present study, a major difference is that ox
dized quercetin preferentially reacts with thiols, whereas oxidized monoHER 
preferentially reacts with ascorbate. This is an essential difference in the inte
play of both flavonoids with antioxidants of the endogenous antioxidant ne
work.  
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The different position of monoHER and quercetin in the network has to origi-
nate from an intrinsic difference in the chemical nature of their oxidation prod-
ucts. Quantum chemical calculations revealed that of the four possible tauto-
meric forms of oxidized quercetin, the tautomer shown in Figure 5A, has an 
abundance of more than 99%. In this tautomer the distance between the elec-
tron deficient carbonyl centers is maximal, which is energetically favorable and 
explains its high abundance. The high abundance of this specific tautomer is 
corroborated by the formation of adducts in the A ring, i.e. 6-GSH-quercetin and 
8-GSH-quercetin, in the reaction of GSH with oxidized quercetin (Galati et al., 
2001). 
In monoHER a rutinose is attached to the 3-OH group of the C ring and a 
hydroxyethyl group is attached to the hydroxyl group oxygen at position 7 of 
the A ring. These substitutions preclude the formation of quinone methide 
tautomers in oxidized monoHER. Therefore, only the ortho-quinone can be 
formed (Figure 5B). In this ortho-quinone two carbonyls are adjacent, which is 
energetically unfavorable compared to the larger distance between these 
groups in the preferential tautomer of oxidized quercetin. The presence of an 
ortho-quinone in the B ring is corroborated by the formation of an adduct in 
this ring, i.e. 2'-GSH-monoHER, in the reaction of oxidized monoHER with GSH 
(Jacobs et al., 2009).  
Apparently, the oxidation products of monoHER and quercetin are ener-
getically different. The LUMO of oxidized monoHER is primarily concentrated in 
the B ring and therefore relatively high, while that of oxidized quercetin is 
spread over the whole molecule (Figure 5). This is reflected by a LUMO of oxi-
dized quercetin (0.0605 kJ/mol) that is substantially lower than that of oxidized 
monoHER (42.6 kJ/mol). Pearson’s HSAB concept assigns the terms ‘hard’ or 
‘soft’ to chemical species to explain or predict the outcome of a chemical reac-
tion (Pearson, 1963). ‘Hard’ applies to electrophiles (the reactants that accept 
binding electrons) that have LUMO of high energy or nucleophiles (the reac-
tants that donate binding electrons) with a low HOMO energy. ‘Soft’, on the 
other hand, applies to electrophiles with a low LUMO value or nucleophiles with 
a high HOMO value. According to the HSAB concept, hard electrophiles react 
faster and form stronger bonds with hard nucleophiles, whereas soft electro-
philes react faster and form stronger bonds with soft nucleophiles. 
Based on their LUMO values, oxidized quercetin is a softer electrophile than 
oxidized monoHER. The reaction of GSH with both oxidized monoHER and 
quercetin is a Michael addition in which GSH acts as a nucleophile. The reaction 
with ascorbate is a redox reaction in which ascorbate finally donates two elec-
trons to the oxidized products. GSH is a relatively soft nucleophile (HOMO value 
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of -1.35 kJ/mol) compared to ascorbate (HOMO value of 
explain the preferential reaction of the soft electrophile, oxidized quercet
with thiols over ascorbate. Oxidized monoHER, on the other hand, is a harder 
electrophile than oxidized quercetin explaining its preference for the harder 
nucleophile ascorbate over GSH. Moreover, as depicted in Fig
part of ascorbate can approach the active part of oxidized monoHER by a h
drogen bond and a π-π interaction between as
The reaction between oxidized monoHER and ascorbate is presented step by 
step in Figure 6B. 
Figure 6. Chemical reaction of oxidized monoHER with ascorbate.
dized monoHER (left) and ascorbate (right). The active part of ascorbate and the active part of 
oxidized monoHER are indicated by the dotted
oxidized monoHER with ascorbate. Only the active parts are shown to illustrate the suggested 
mechanism more clearly. (1) The active part of ascorbate (top) approaches the active part of ox
dized monoHER (bottom) due to a π-π interaction and a hydrogen bond. The 
bate are used to create a new bond. The C3 of ascorbate will most likely attack the C3’ of the 
monoHER quinone because it is more electron deficient than the C4’ according to Spar
After the attack, a transition state, with an sp3
suggested to be formed. (3) This intermediate rapidly decomposes into monoHER and oxidized 
ascorbate. The driving force of this reaction is the r
monoHER. 
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Based on our findings, the following concept is proposed. Flavonoids easily pick 
up the reactivity of radicals due to their superior scavenging activity. This reac-
tivity is directed in different ways by the two flavonoids studied (Figure 7). 
Quercetin directs this reactivity towards thiols. Conjugation of oxidized querce-
tin with GSH is primarily a cellular defense mechanism to alleviate the harmful 
consequences of the reactive quinone metabolite (O'Brien, 1991). However, this 
will reduce GSH levels and thus weaken the endogenous antioxidant network. 
Moreover, in e.g. blood plasma, where GSH is practically absent, or when GSH 
has been depleted, oxidized quercetin will react with protein thiols. This causes 
toxicity such as increased membrane permeability (Yen et al., 2003) or impaired 
functioning of enzymes that contain a critical thiol-group (Kalyanaraman et al., 
1987; Moore et al., 1988). In contrast to quercetin, monoHER preferentially 
directs its acquired reactivity towards ascorbate. In human blood plasma, oxi-
dized monoHER, contrary to oxidized quercetin, does not react with plasma 
protein thiols. Ascorbate present in plasma reduces oxidized monoHER to the 
parent compound and prevents that oxidized monoHER reacts with thiols. The 
oxidized ascorbate formed in this recycling of monoHER can also be regene-
rated in the network, e.g. by dehydroascorbate reductase that uses NADH as 
cofactor. In this way, the reactivity is completely neutralized and the antioxi-
dant network is restored. Thus, the advantage of monoHER is that it can func-
tion as a catalyst that safely channels the reactivity of radicals into the endo-
genous antioxidant network. This advantage might have been involved in the 
superior effect of monoHER over other structurally related flavonoids (van Ack-
er et al., 1993) in our screening procedure for protection against doxorubicin-
induced cardiotoxicity. To conclude, our study demonstrates that structurally 
related flavonoids, belonging to the same subgroup and displaying a compara-
ble radical scavenging activity, can have a different impact on health. 
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Figure 7. Interplay of monoHER and quercetin with the endogenous 
Schematic representation of the endogenous antioxidant network. Free radicals are scavenged by 
antioxidants in the network, such as GSH and ascorbate. In this way, free radicals are neutralized. 
Free radicals that are not neutralized can damage e.g. proteins, lipids and DNA. (B) The flavonoid 
quercetin is an excellent radical scavenger. During the scavenging of free radicals quercetin b
comes oxidized. After oxidation of quercetin, four tautomeric forms of the oxidation product can 
antioxidant network. (A) 
e-
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be formed. In the figure the tautomer which has an abundance of more than 99% is shown. When 
ascorbate and GSH are present in the same concentration, oxidized quercetin reacts much faster 
with GSH than with ascorbate, thereby forming 6-GSH-quercetin and 8-GSH-quercetin. Because of 
its high reactivity towards thiols, oxidized quercetin is also prone to react with protein thiols, as 
was seen in human blood plasma. This reaction of oxidized quercetin is not prevented by ascorbate 
and can lead to toxicity. (C) The oxidation product formed out of monoHER is an ortho-quinone. 
Ascorbate recycles this oxidation product to the parent compound monoHER, while GSH forms a 
conjugate with oxidized monoHER, i.e. 2’-GSH-monoHER. When both compounds are present in 
the same concentration, oxidized monoHER reacts rather with ascorbate (73%) than with GSH 
(27%). The oxidized ascorbate formed in this recycling can be regenerated in the network, e.g. by 
dehydroascorbate reductase (DHAR) that uses NADH as cofactor. Thus, the advantage of monoHER 
is that it can safely channel the non-specific reactivity of radicals toward ascorbate, which can be 
regenerated in the antioxidant network. 
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Abstract 
BACKGROUND: Despite therapeutic advances, the prognosis of patients with 
metastatic soft tissue sarcoma (STS) remains extremely poor. The results of a 
recent clinical phase II study, evaluating the protective effects of the semisyn-
thetic flavonoid 7-mono-O-(β-hydroxyethyl)-rutoside (monoHER) on doxorubi-
cin-induced cardiotoxicity, suggest that monoHER enhances the antitumour 
activity of doxorubicin in STSs.  
METHODS: To molecularly explain this unexpected finding, we investigated the 
effect of monoHER on the cytotoxicity of doxorubicin, and the potential in-
volvement of glutathione (GSH) depletion and nuclear factor-κB (NF-κB) inacti-
vation in the chemosensitising effect of monoHER.  
RESULTS: MonoHER potentiated the antitumour activity of doxorubicin in the 
human liposarcoma cell line WLS-160. Moreover, the combination of monoHER 
with doxorubicin induced more apoptosis in WLS-160 cells compared with dox-
orubicin alone. MonoHER did not reduce intracellular GSH levels. On the other 
hand, monoHER pretreatment significantly reduced doxorubicin-induced NF-κB 
activation.  
CONCLUSION: These results suggest that reduction of doxorubicin-induced NF-
κB activation by monoHER, which sensitises cancer cells to apoptosis, is in-
volved in the chemosensitising effect of monoHER in human liposarcoma cells. 
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Introduction 
Soft tissue sarcomas (STSs) comprise a rare and diverse group of malignancies 
from mesenchymal origin, accounting for ~ 1% of all adult malignancies (Jemal 
et al., 2009). The only single agents that are consistently associated with re-
sponse rates of about 25% in metastatic STS are doxorubicin and ifosfamide 
(Keohan and Taub, 1997; Santoro et al., 1995).  
In a clinical phase II study with metastatic cancer patients (Bruynzeel et al., 
2007), evaluating the protective effects of the semisynthetic flavonoid 7-mono-
O-(β-hydroxyethyl)-rutoside (monoHER) on doxorubicin-induced cardiotoxicity 
(Bast et al., 2007), we unexpectedly observed that of the four patients diag-
nosed with STS, three experienced objective remissions, whereas the fourth had 
stable disease. This observed 75% response rate is much better than the ex-
pected 25%. This prompted us to further study the sensitising effect of mono-
HER on doxorubicin-induced cytotoxicity. 
MonoHER, like other flavonoids, may have an influence on the pathways 
that are involved in the development of resistance against doxorubicin 
(Kachadourian and Day, 2006; Sarkar and Li, 2007). Nuclear factor-κB (NF-κB) is 
one of the key factors involved in the development of chemoresistance (Baud 
and Karin, 2009; Karin, 2006; Sarkar and Li, 2008). It has been reported that 
chemotherapeutic agents, including doxorubicin, induce the activation of NF-κB 
in cancer cells (Chuang et al., 2002), thereby inducing survival signals that in-
hibit apoptosis and promote cancer cell growth. Besides NF-κB activation, in-
creased glutathione (GSH) levels in cancer cells have also been associated with 
multidrug resistance of many tumours, as GSH can conjugate with the chemo-
therapeutic agent, leading to drug inactivation and excretion (Estrela et al., 
2006).  
Therefore, to support our clinical finding, we evaluated the effects of 
monoHER and doxorubicin on tumour cell growth, apoptosis, intracellular GSH 
levels and NF-κB activation in human STS cell lines.  
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Materials and methods 
Cell culture and reagents 
The human STS cell lines SKUT-1 (leiomyosarcoma), SKLMS-1 (leiomyosarcoma), 
HT-1080 (fibrosarcoma) and WLS-160 (liposarcoma) (Medical Oncology, VU 
University medical center, Amsterdam, The Netherlands) were cultured under 
standard conditions. Novartis Consumer Health (Nyon, Switzerland) kindly pro-
vided 7-mono-O-(β-hydroxyethyl)-rutoside (monoHER). From Sigma (St Louis, 
MO, USA), L-buthionine (SR)-sulphoximine (BSO) was purchased and doxorubi-
cin HCl (2 mg ml
-1
) was obtained from Pharmacia Upjohn BV (Woerden, the 
Netherlands). All other chemicals were of analytical grade. 
Cell growth inhibition by sulphorhodamine B assay 
The human STS cell lines were either untreated or pretreated with 50 µM mo-
noHER. After 1 h incubation, medium was removed and replaced with fresh 
medium containing different concentrations of doxorubicin (0.001-10 µM). 
After 72 h of incubation, cell viability was examined by the sulphorhodamine B 
assay (Vichai and Kirtikara, 2006).  
Caspase-3/7 assay for detecting apoptosis 
WLS-160 cells were either untreated or pretreated with 50 µM monoHER for 1 
h, and then exposed to 10 µM doxorubicin for an additional 6 h. After treat-
ment, activation of caspase-3/7 was quantified by the Caspase-Glo 3/7 assay kit 
(Promega Corporation, Madison, WI, USA).  
Measurement of intracellular GSH 
WLS-160 cells were incubated with 50 µM monoHER or 50 µM BSO for 1, 6 or 
24 h. After incubation, cells were washed with PBS, harvested by treatment 
with trypsin-EDTA (Gibco, Paisley, UK) and washed again with ice-cold PBS (Gib-
co). After centrifugation, cells were resuspended in ice-cold extraction buffer 
(0.1% Triton X-100 and 0.6% SSA, Sigma) and sonicated in icy water for 2-3 min. 
The extracts were used for determination of intracellular GSH using an enzy-
matic recycle method (Rahman et al., 2006). 
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Nuclear factor-κB measurement 
WLS-160 cells were treated with 10 µM doxorubicin for 1.5, 3, 6 or 24 h. In 
another experiment, the cells were either untreated or pretreated for 1 h with 
50 µM monoHER before doxorubicin exposure (10 µM; 6 h). Nuclear factor-κB 
expression was determined in nuclear extracts of the cells (Hofmann et al., 
1999) using the TransAM NF-κB p50 transcription factor assay kit (Active Motif, 
Rixensart, Belgium). Protein concentrations were determined using the method 
of Bradford (Biorad, Veenendaal, The Netherlands). 
Statistical analysis 
All experiments were performed, at least, in triplicate. Results are given as 
mean ± s.d. or as a typical example. The statistical significance of the differences 
between experimental groups and controls was determined by Student’s t-test. 
P-values ≤ 0.05 were considered statistically significant. 
Results 
As shown in Table 1, monoHER pretreatment did not significantly influence the 
antitumour activity of doxorubicin in SKUT-1, SKLMS-1 and HT-1080 cells. How-
ever, pretreatment of the liposarcoma cell line, WLS-160, with 50 µM monoHER 
for 1 h before doxorubicin exposure shifted the growth inhibition curve of dox-
orubicin to the left (Figure 1A). MonoHER alone did not affect tumour growth. 
These results indicate that monoHER potentiated the antitumour activity of 
doxorubicin in WLS-160 cells. 
 
Table 1. IC  values (μM) of growth inhibition by doxorubicin.50
a 
Human STS cell line Doxorubicin Doxorubicin + monoHER 
SKLMS-1 0.063 ± 0.009 0.066 ± 0.007 
SKUT-1 0.048 ± 0.008 0.045 ± 0.009 
HT-1080 0.024 ± 0.005 0.027 ± 0.006 
WLS-160 0.016 ± 0.003 0.0075 ± 0.001* 
Abbreviations: IC50 = inhibitory concentration 50%; monoHER = 7-mono-O-(β-hydroxyethyl)-
rutoside, 
a 
Data are expressed as mean ± s.d. * P ≤ 0.05. 
 
The effect of monoHER on doxorubicin-induced apoptosis in WLS-160 cells as 
assessed by caspase-3/7 activation is shown in Figure 1B. Doxorubicin treat-
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ment (10 µM; 6 h) strongly induced caspase-3/7 activity. Pretreatment of the 
cells with 50 µM monoHER for 1 h before doxorubicin exposure significantly 
enhanced the doxorubicin-induced caspase-3/7 activation. MonoHER alone had 
no effect on caspase-3/7 activity. These findings indicate that monoHER sensi-
tised these cancer cells to doxorubicin-induced apoptosis. 
Figure 1. Effect of the semisynthetic flavonoid monoHER on the cytotoxic effects of doxorubicin in 
the liposarcoma cell line WLS-160. (A) MonoHER pretreatment (50 µM; 1 h) significantly enhances 
the cell growth inhibition induced by doxorubicin (0.001-0.1 µM; 72 h) (mean ± s.d. *P≤0.05 com-
pared with doxorubicin treatment). (B) MonoHER pretreatment (50 µM; 1 h) significantly enhances 
the apoptosis induced by doxorubicin (10 µM; 6 h) (mean ± s.d. *P≤0.05 compared with doxorubi-
cin treatment). Relative light units (RLUs); doxorubicin (DOX). (C) MonoHER treatment (50 µM; 1, 6 
and 24 h) has no effect on the intracellular GSH concentration, whereas BSO (50 µM; 1, 6 and 24 h) 
reduces GSH levels in a time-dependent manner (mean ± s.d. *P≤0.05 compared with control). (D) 
MonoHER pretreatment (50 µM; 1 h) significantly prevents doxorubicin-induced (10 µM; 6 h) NF-
κB activation (mean ± s.d. *P≤0.05 compared with doxorubicin treatment). 
 
As shown in Figure 1C, treatment of WLS-160 cells with 50 µM monoHER for 1, 
6 or 24 h did not affect intracellular GSH levels. In contrast, the GSH synthesis 
inhibitor BSO induced a time-dependent GSH depletion in WLS-160 cells. More-
over, BSO also enhanced the antitumour activity of doxorubicin (data not 
shown). These results indicate that intracellular GSH depletion can sensitise 
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WLS-160 cells to doxorubicin-induced apoptosis. However, this mechanism is 
not involved in the chemosensitising effects of monoHER. 
Doxorubicin treatment (10 µM; 1.5, 3, 6 and 24 h) significantly induced NF-
κB DNA-binding activity in WLS-160 cells compared with untreated controls. 
Within the measured time range, NF-κB activation was maximal at 6 h of drug 
exposure (data not shown). Figure 1D shows that pretreatment of cells with 50 
µM monoHER for 1 h before 6 h of doxorubicin exposure significantly reduced 
doxorubicin-induced activation of NF-κB. MonoHER alone had no effect on the 
basal NF-κB level in WLS-160 cells. These results suggest that reduction of 
doxorubicin-induced NF-κB activation might be involved in the sensitising effect 
of monoHER on the antitumour effect of doxorubicin. 
Discussion 
In this paper, we show that monoHER can enhance the cytotoxicity of doxorubi-
cin, possibly via modulation of NF-κB.  
Four different human STS cell lines were investigated. Only in the liposar-
coma cell line, WLS-160, pretreatment with monoHER resulted in a significantly 
greater inhibition of cancer cell growth. This different response on monoHER 
pretreatment between the different cell lines is possibly because of the known 
large diversity in STS and the subsequent response to chemotherapy (Van Glab-
beke et al., 1999; Verweij, 2009). The molecular mechanism behind the ob-
served sensitising effect of monoHER in the responding liposarcoma cell line, 
WLS-160, was further explored. 
First, we investigated how cytotoxicity of doxorubicin and the chemosensi-
tising effect of monoHER were mediated. Doxorubicin as a single agent acti-
vated caspase-3/7 activity and thus induced apoptosis in WLS-160 cells. Pre-
treatment of these cells with monoHER resulted in a significantly greater induc-
tion of apoptosis. These results suggest that the greater degree of cancer cell 
death by the combination of monoHER with doxorubicin is mediated by the 
induction of an apoptotic pathway. 
As multidrug resistance of many cancer cells is associated with increased in-
tracellular GSH levels, GSH depletion is a potential strategy to sensitise tumour 
cells to chemotherapeutics and modify drug resistance (Estrela et al., 2006; 
Meister, 1991). This can be achieved by inhibitors of GSH synthesis such as BSO, 
a selective and irreversible inhibitor of γ-glutamylcysteine synthase, the rate 
limiting enzyme of GSH synthesis (Han and Park, 2009). As also shown by our 
results, BSO efficiently enhances the effect of several chemotherapeutic drugs 
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including doxorubicin (Vanhoefer et al., 1996). In addition, some flavonoids can 
also deplete GSH levels in cancer cells, thereby sensitising these cancer cells to 
chemotherapy (Kachadourian and Day, 2006; Kachadourian et al., 2007; Ramos 
and Aller, 2008). Because monoHER is able to form a GSH-monoHER adduct that 
might deplete cells from GSH (Jacobs et al., 2009), we examined whether 
monoHER can deplete GSH in WLS-160 cells. However, in contrast to BSO, 
monoHER did not significantly change GSH levels in WLS-160 cells, suggesting 
that the growth-inhibitory effect of monoHER is not mediated via GSH deple-
tion. 
Another crucial factor involved in drug resistance is NF-κB, an inducible and 
ubiquitously expressed transcription factor that regulates cell survival, inflam-
mation and differentiation (Karin, 2006). Many chemotherapeutic agents induce 
the activity of NF-κB, which causes drug resistance in cancer cells (Sarkar and Li, 
2008). Because doxorubicin rapidly induced NF-κB activity in WLS-160 cells 
within 6 h, inhibition of NF-κB was expected to enhance the antitumour activity 
of doxorubicin, similar to several in vitro and preclinical in vivo studies in which 
the regulation of NF-κB enhanced the efficacy of chemotherapy (Bava et al., 
2005; Li et al., 2005; Nakanishi and Toi, 2005; Sung et al., 2007). Our results 
show that monoHER prevented the NF-κB induction by doxorubicin in WLS-160 
cells, suggesting that downregulation of NF-κB activation by monoHER may be 
responsible for the sensitisation of these cancer cells to doxorubicin. Figure 2 
further illustrates this mechanism. 
In conclusion, monoHER enhanced the cytotoxicity of doxorubicin in the 
human liposarcoma cell line WLS-160. This potentiation was not mediated by 
GSH depletion, but monoHER reduced doxorubicin-induced NF-κB activation, 
thereby sensitising tumour cells to apoptosis. Thus, the high response rate in 
the clinical phase II study may be mediated by reduction of doxorubicin-induced 
NF-κB activation. For certain STS patients, monoHER might improve chemother-
apy and even decrease systemic toxicity. Moreover, monoHER might also be 
valuable for the treatment of other tumours that have developed chemoresis-
tance through NF-κB activation. However, future studies are needed to further 
elucidate the value of adding monoHER to the chemotherapeutic treatment 
with doxorubicin. 
 
P O T E N T I A T I O N  O F  D O X O R U B I C I N  A C T I V I T Y  B Y  M O N O H E R  
 85 
Figure 2. Suggested pathway illustrating the influence of monoHER on doxorubicin cytotoxicity in 
WLS-160 cells. Under resting conditions, NF-κB is maintained in an inactive state in the cytoplasm 
via interaction with the inhibitory protein, IκB. Doxorubicin can activate the NF-κB pathway, which 
involves the phosphorylation, ubiquitination and proteasomal degradation of IκB. Nuclear factor-
κB is then free to translocate to the nucleus where it facilitates the transcription of, for example, 
antiapoptotic genes, resulting in less tumour cell killing and the development of drug resistance. 
MonoHER is able to reduce this doxorubicin-induced NF-κB activation, thereby sensitising WLS-160 
cells to doxorubicin-induced apoptosis.  
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Abstract 
The clinical use of the anticancer drug doxorubicin is limited by severe cardi-
otoxicity. In mice, the semisynthetic antioxidant flavonoid 7-mono-O-(β-
hydroxyethyl)-rutoside (monoHER) has been successfully used as a protector 
against doxorubicin-induced cardiotoxicity. However, most monoHER has al-
ready been cleared from the body at the time that doxorubicin concentrations 
are still high. This result suggests that not only the parent compound monoHER 
itself but also monoHER metabolites could be responsible for the observed 
cardioprotective effects in mice. Therefore, in the present study, we investi-
gated the metabolism of monoHER in mice. Mice were administered 500 mg/kg 
monoHER intraperitoneally. At different time points after monoHER administra-
tion, bile was collected and analyzed for the presence of monoHER metabolites. 
The formed metabolites were identified by liquid chromatography-diode array 
detection-time of flight-mass spectrometry. Thirteen different metabolites were 
identified. The observed routes of monoHER metabolism are methylation, glu-
curonidation, oxidation of its hydroxyethyl group, GSH conjugation, and hydro-
lysis of its disaccharide. In line with other flavonoids, methylated monoHER and 
the monoHER glucosides are expected to have relatively high cellular uptake 
and low clearance from the body. Therefore, these metabolites might contri-
bute to the observed protection of monoHER against doxorubicin-induced car-
diotoxicity. 
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Introduction 
Doxorubicin is a very effective antitumor agent, widely used in the treatment of 
different types of cancer. Unfortunately, treatment with doxorubicin is limited 
by a cumulative dose-dependent cardiotoxicity, which manifests itself as con-
gestive heart failure (Bast et al., 2007; Lipshultz et al., 2005; Singal and Iliskovic, 
1998). Although the mechanism of doxorubicin-induced cardiotoxicity is still not 
fully understood, the formation of free radicals by doxorubicin semiquinones 
seems to be implicated (Horenstein et al., 2000; Xu et al., 2001). Cardiac tissue 
is particularly vulnerable to free radical-induced injury because its antioxidant 
protection by enzymes such as superoxide dismutase and catalase is markedly 
reduced compared with that of other tissues in the body (Doroshow et al., 
1980; Iarussi et al., 2000; Julicher et al., 1988).  
The semisynthetic flavonoid 7-mono-O-(β-hydroxyethyl)-rutoside (mono-
HER) is a constituent of the registered drug Venoruton, which is used in the 
treatment of chronic venous insuffiency (Petruzzellis et al., 2002). In a series of 
structurally related flavonoids, monoHER was found to be the most potent an-
tioxidant (Haenen et al., 1993). As for most flavonoids, monoHER consists of 
three rings referred to as the A, B and C rings (Figure 1). It also contains a 3’,4’-
catechol moiety in the B ring and a C2-C3 double bond and 4-oxo function in the 
C ring, which contribute to its high antioxidant activity. Further characteristic 
structural features of monoHER are the rutinose group (glucose + rhamnose) at 
the 3-O position in the C ring and the hydroxyethyl group at the 7-O position in 
the A ring. 
Figure 1. Structural formula of monoHER, including its fragmentation as shown by its mass spec-
trum obtained by tandem mass spectrometry.  
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Preclinical experiments in mice have shown that monoHER administration be-
fore doxorubicin effectively protects against doxorubicin-induced cardiotoxicity, 
without interfering with its antitumor activity (van Acker et al., 2000; van Acker 
et al., 1997). Of interest, the half-lives of monoHER in plasma and heart tissue 
(11.8 and 16.2 min, respectively) are much lower than those of doxorubicin 
(12.6 and 11.5 h, respectively) (Abou El Hassan et al., 2003a; Abou El Hassan et 
al., 2003b). In addition, monoHER cannot be detected for longer than 2 h after 
administration, whereas doxorubicin is present in plasma for at least 48 h after 
administration. This result means that monoHER has already been cleared from 
the body at the time that doxorubicin concentrations are still relatively high and 
suggests that not only the parent compound monoHER itself but also monoHER 
metabolites might be responsible for the observed cardioprotective effects in 
mice. Moreover, evidence with other polyphenols that metabolites may me-
diate or substantially contribute to the pharmacological efficacy of the parent 
molecule is accumulating, as is observed with flavonoids in grapes and wine 
(Forester and Waterhouse, 2009; Gescher and Steward, 2003). Therefore, iden-
tifying the metabolites of compounds is of great importance. Up to the present 
no metabolites were found in plasma or urine from mice and humans in our 
studies with monoHER (Abou El Hassan et al., 2003b; Willems et al., 2006). Ear-
lier studies with radiolabeled monoHER in mice and rats reported that the liver 
was the main drug-eliminating organ. A major unidentified metabolite was 
found in bile, which was suggested to be a glucuronide of monoHER (Barrow 
and Griffiths, 1974; Hackett and Griffiths, 1977a). In addition, enterohepatic 
cycling has been described previously (Hackett and Griffiths, 1977b).  
To further elucidate the protective effect of monoHER, the objective of this 
study was to investigate the metabolism of monoHER in mice and characterize 
its metabolites. This was realized by analyzing the bile fluid of mice that re-
ceived monoHER for the presence of monoHER and possible monoHER metabo-
lites using LC-DAD-TOF-MS analysis.  
Materials and methods 
Chemicals 
7-Mono-O-(β-hydroxyethyl)-rutoside was provided by Novartis Consumer 
Health (Nyon, Switzerland). MonoHER was dissolved in 36 mM NaOH in sterile 
water, giving a final concentration of 33 mg/ml. Catechol-O-methyltransferase 
(COMT), S-adenosyl-L-methionine (SAM), dithiothreitol, and MgCl2 were ob-
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tained from Sigma-Aldrich (St. Louis, MO). Trifluoroacetic acid (TFA) and NaOH 
were purchased from Sigma-Aldrich (Steinheim, Germany). Acetonitrile HPLC 
grade, methanol, and dimethyl sulfoxide were obtained from Biosolve (Val-
kenswaard, The Netherlands). 
Animals 
Eighteen male BALB/c mice (8 weeks old, 20-25 g) purchased from Charles River 
(Maastricht, The Netherlands) were kept in a light- and temperature-controlled 
room (21-22 °C, humidity 60-65%). The animals were fed a standard diet and 
were allowed to eat and drink tap water ad libitum. The animals were allowed 
to adapt to the laboratory housing conditions for at least 1 week before the 
experiment was started. 
Experimental design 
The protocol was approved by the Ethics Committee for Animal Experiments of 
Maastricht University (Maastricht, The Netherlands). The mice were adminis-
tered 500 mg/kg monoHER intraperitoneally. At different time points after mo-
noHER administration (15, 60, 120, 180, and 240 min), three mice were sacri-
ficed, and the gallbladder was collected. One group of mice received no mo-
noHER; the bile of these mice served as a blank. Immediately after collection, 
the gallbladder was transferred into polypropylene micro-test tubes and frozen 
at - 80°C until analysis. 
Sample preparation 
Each gallbladder was perforated and mixed with 50 µl of dimethyl sulfoxide-
methanol (1:4, v/v). The mixture was vortexed and centrifuged (17060g, 15 
min). The supernatant was removed and injected onto the LC column.  
LC-DAD analysis 
LC-DAD of the bile samples was performed on an Agilent 1100 series LC-DAD 
system (Agilent Technologies, Santa Clara, CA). Analytical separations were 
achieved using an ODS-3 column (5 μm, 250 x 3 mm) (Inertsil; Varian Inc., Palo 
Alto, CA) at 40 °C. The mobile phase consisted of ultrapure water containing 
0.1% (v/v) TFA (mobile phase A) and acetonitrile containing 0.1% (v/v) TFA (mo-
bile phase B). The gradient was started at t = 0 min with 85% (v/v) A, was 
changed linearly over the first 20 min to 30% (v/v) B followed by an increase to 
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90% (v/v) B at t = 25 min, and was then stationary for 1 min. The column was 
reequilibrated with 15% (v/v) B for 5 min. A flow rate of 1 ml/min and
 
an injec-
tion volume of 10 µl were used. Detection was performed with a DAD. The 
chromatograms presented are based on detection at 355 nm.  
LC-DAD-TOF-MS analysis 
LC-DAD-TOF-MS, including fragmentation and exact mass measurements, was 
performed using an Agilent 1100 LC-DAD-TOF-MS system (Agilent Technologies) 
to further characterize the peaks in the LC chromatogram. The UV signal at 355 
nm was collected. Electrospray ionization was performed in positive mode with 
the following conditions: m/z range 50 to 3000, 175 V fragmentor (varied for 
fragmentation experiments), 0.1 m/z step size, 1.013 cycles/s, 350°C drying gas 
temperature, 10 liters of N2/min drying gas, 35 psig nebulizer pressure, and 2 kV 
capillary voltage. The MS data were collected using internal reference mass 
correction. The reference substances [purine at 121.050873 Da and hexakis-
(1H,1H,3H-tetrafluoro-pentoxy)phosphazene (HP-921) at 922.009798 Da] were 
constantly injected in the electrospray ion source equipped with a dual-sprayer 
mechanism. The LC conditions were the same as described above. The LC-DAD-
TOF-MS system was controlled using MassHunter qualitative analysis software 
(B03.01; Agilent Technologies). 
Elemental composition calculations from the exact masses were performed 
off-line using MassHunter. This software was used to work with the spectrum 
manually generated for every peak. Potential assignments were calculated us-
ing the monoisotopic masses with specifications of a tolerance of 10 ppm devia-
tion. The number and types of expected atoms were set as follows: carbons 
<60, hydrogens <120, oxygens <30, nitrogens <30, and sulfurs <5, whereas the 
double bond equivalent was set to <50. 
Quantification of monoHER metabolites 
Quantification of the different metabolites was achieved by their UV response 
at 355 nm. Quantification of metabolites is normally achieved using external 
calibration with reference standards. However, no commercial reference stan-
dards were available for these metabolites. Therefore, it was assumed that the 
UV response at 355 nm is equal to that of monoHER for all metabolites. This is a 
reasonable assumption because the UV spectra in the 355 nm region of all me-
tabolites are similar to that of monoHER.  
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The relative amounts of the metabolites were estimated by calculating the area 
under the curve (AUC) from the concentration-time curve of each metabolite, 
using the trapezoidal rule, and expressing this as percentage of the total AUC of 
all detected compounds together.  
Synthesis of 4’-methyl-monoHER 
MonoHER was enzymatically methylated using the enzyme COMT and the me-
thyl donor SAM. The reaction mixture for the enzymatic O-methylation of mo-
noHER consisted of 100 µM monoHER, 20 U of COMT, 1 mM SAM, 1.2 mM 
MgCl2, and 1 mM dithiothreitol in a final volume of 1 ml Tris-HCl buffer. The 
mixture was incubated at 37°C for 24 h and then analyzed by the LC-DAD pro-
cedure described above. 
1
H NMR analysis identified the formed metabolite as 
4’-methyl-monoHER. To verify the presence of 4’-methyl-monoHER in the col-
lected bile samples, bile fluid was spiked with this metabolite and analyzed by 
LC-DAD. 
Results 
Bile samples collected after monoHER administration contain several com-
pounds that are absent in the blank bile (Figure 2). The DAD spectra of these 
compounds and the absorption maxima at 355 nm are similar to those of mo-
noHER, indicating that these compounds are metabolites of monoHER. LC-DAD-
TOF-MS was used to further identify these metabolites. Six major metabolites 
(M1-M6), representing more than 90% of all detected compounds, and seven 
minor metabolites (M7-M13) were detected. The mass ([M+H]
+
), main fragment 
ions, and the proposed compound name of each metabolite are listed in Table 
1. In Table 2, the exact mass determination data and the corresponding chemi-
cal formulas are summarized. 
Parent 
The peak in the LC chromatogram with a retention time of 8.5 min elutes at the 
same retention time as the parent compound monoHER. LC-MS analysis re-
vealed m/z of 655, which corresponds to a molecular mass of 654 Da (Table 1). 
Tandem mass spectrometry fragmentation produced three key fragments: m/z 
509 (- 145, loss of rhamnose sugar), m/z 347 (- 307, loss of rhamnose and glu-
cose sugar), and m/z 303 (- 351, loss of rhamnose, glucose, and the hydroxye-
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thyl group of the A ring) (Figure 1). This fragmentation pattern is similar to the 
fragmentation of monoHER. In addition, the elemental composition (C29H34O17) 
generated by exact mass measurements (Table 2) is identical to that of the par-
ent compound, identifying this compound as monoHER. 
 
Figure 2. Representative LC chromatograms of (A) blank bile and (B) bile collected from mice 60 
min after monoHER administration. The numbered peaks represent monoHER [parent (P)] and its 
six major metabolites (M1-M6). The chromatograms presented are based on detection at 355 nm. 
Major metabolites 
M1 and M2. Metabolites M1 and M2 have an m/z 176 Da higher than monoH-
ER. This finding indicates that the metabolites are glucuronidated derivatives of 
monoHER. In addition, the fragments are similar to that of monoHER, only 176 
Da higher (Table 1). The chemical formula (C35H42O23) generated by exact mass 
measurements confirms the formation of monoHER glucuronide (Table 2). 
M3. LC-MS analysis revealed that the main fragments of metabolite M3 are 
14 Da higher than monoHER glucuronide (m/z 699, 537, 361, and 317) (Table 1). 
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Exact mass determination and the corresponding chemical composition 
(C36H44O23) show the addition of a methyl group (+CH2) to monoHER glucuron-
ide (Table 2), identifying this peak as methyl-monoHER glucuronide. 
 
Table 1. MonoHER and its metabolites identified in bile of mice by LC-DAD-TOF-MS. 
 tR 
(min) 
Compound [M+H]
+
 
(m/z) 
Mass change 
from parent 
Main fragment ions (m/z) 
  Parent compound    
P 8.5 monoHER 655 0 509, 347, 303 
  Major metabolites    
M1 5.6 monoHER glucuronide 831 + 176 765, 685, 523, 347, 303 
M2 6.3 monoHER glucuronide 831 + 176 765, 685, 523, 347, 303 
M3 6.9 methyl-monoHER glucuronide 845 + 190 699, 537, 361, 317 
M4 9.7 monoCER 669 + 14 523, 463, 361 
M5 11.1 methyl-monoHER 669 + 14 523, 361, 317 
M6 12.3 methyl-monoCER 683 + 28 537, 375 
  Minor metabolites    
M7 3.4 GSH-monoHER 960 + 305 814, 705, 652, 523, 371 
M8 7.1 monoHER diglucuronide 1007 + 352 861, 845, 831, 699, 523, 347 
M9 7.6 methyl-monoHEG 523 - 132 479, 361, 303 
M10 7.8 monoCER glucuronide 845 + 190 537, 361 
M11 8.8 methyl-monoCER glucuronide 859 + 204 551, 375 
M12 12.5 dimethyl-monoHEG 537 - 118 375 
M13 14.8 dimethyl-monoHER 683 + 28 537, 375 
  Impurities/metabolites    
M14 9.4 diHER 699 + 44 655, 523, 347 
M15 12.5 triHER 743 + 88 622, 597, 435, 347 
M16 13.3 methyl-diHER 713 + 58 537, 361 
M17 14.8 dimethyl-diHER 727 + 72 537, 439, 361 
 
M4. The main fragments of metabolite M4 are 14 Da higher than monoHER 
(m/z 523 and 361) (Table 1). The chemical formula (C29H32O18) indicates that 
this metabolite has two hydrogen atoms less and one oxygen atom more (-H2 + 
O) than monoHER (Table 2). This finding points to the oxidation of the hydrox-
yethyl group in the A ring of monoHER to a carboxyethyl group, thereby gene-
rating 7-mono-O-(β-carboxyethyl)-rutoside (monoCER). 
M5. Metabolite M5 shows main fragments similar to monoHER, only 14 Da 
higher (m/z 523, 361, and 317) (Table 1). On the basis of the mass spectral data 
and the chemical formula (C30H36O17), this metabolite was identified as the me-
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thylated metabolite of monoHER (Table 2). Moreover, the peak area of M5 in 
the chromatogram increased after the bile sample was spiked with enzymati-
cally synthesized 4’-methyl-monoHER. 
M6. Metabolite M6 has an m/z 28 Da higher than monoHER (Table 1). From 
its chemical formula (C30H34O18) it was deduced that the hydroxyethyl group in 
the A ring was oxidized together with the methylation of one of the hydroxyl 
groups of the catechol of monoHER (Table 2). This metabolite was therefore 
identified as methyl-monoCER. 
Minor metabolites 
M7. LC-MS analysis of metabolite M7 shows an m/z 305 Da higher than mo-
noHER, which is indicative of GSH conjugation (Table 1). The peak area of M7 in 
the chromatogram increased after the bile sample was spiked with the synthet-
ic reference standard, 2’-GSH-monoHER (Jacobs et al., 2009), identifying the 
peak as such. 
M8. Metabolite M8 shows an m/z 352 (or 2 x 176) Da higher than the par-
ent compound (Table 1). This indicates the addition of two glucuronic acid 
groups to monoHER and identifies this metabolite as monoHER diglucuronide. 
M9. Metabolite M9 shows an m/z 146 Da lower than methylated monoHER 
(Table 1). The chemical formula (C24H26O13) shows the loss of C6H10O4 (rham-
nose sugar) compared with methyl-monoHER (Table 2). This can be explained 
by hydrolysis of the sugar group (glucose-rhamnose), which is attached to the B 
ring of methyl-monoHER, thereby generating methyl-7-mono-O-(β-
hydroxyethyl)-glucoside (methyl-monoHEG). 
M10. On the basis of the exact mass determination data and the corre-
sponding chemical composition (C35H40O24) (Table 2), metabolite M10 was iden-
tified as monoCER glucuronide. 
M11. LC-MS analysis of metabolite M11 shows the same main fragments as 
monoCER-glucuronide, only 14 Da higher (m/z 551 and 375) (Table 1). On the 
basis of the mass spectral data and its chemical composition (C36H42O24) (Table 
2), this metabolite was identified as methyl-monoCER glucuronide. 
M12. Metabolite M12 shows an m/z 146 Da lower than dimethyl-monoHER 
(Table 1). Accurate mass measurements indicate the loss of the rhamnose sugar 
(C6H10O4) compared with dimethyl-monoHER (Table 2). This metabolite was 
therefore identified as dimethyl-monoHEG. 
M13. Metabolite M13 shows an m/z 28 Da higher than the parent com-
pound (Table 1). The chemical formula (C31H38O17) generated by exact mass 
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measurements shows the addition of two methyl groups (+ 2 x CH2) (Table 2), 
identifying this metabolite as dimethyl-monoHER. 
 
Table 2. Exact mass determinations (TOF-MS). 
 Compound Measured m/z 
([M+H]
+
) 
Calculated m/z 
([M+H]
+
) 
Error 
(ppm) 
Elemental 
composition 
DBE 
P monoHER 655.1872 655.1869 -0.6 C29H34O17 13 
M1/M2 monoHER glucuronide 831.2161 831.2189 3.41 C35H42O23 15 
M3 methyl-monoHER glu-
curonide 
845.2352 845.2346 -0.73 C36H44O23 15 
M4 monoCER 669.1684 669.1661 -3.41 C29H32O18 14 
M5 methyl-monoHER 669.2028 669.2025 -0.38 C30H36O17 13 
M6 methyl-monoCER 683.1838 683.1818 -2.97 C30H34O18 14 
M7 GSH-monoHER 960.2537 960.2551 1.39 C39H49N3O23S1 17 
M8 monoHER diglucuronide 1007.2520 1007.2510 -1.04 C41H50O29 17 
M9 methyl-monoHEG 523.1457 523.1446 -2.07 C24H26O13 12 
M10 monoCER glucuronide 845.2029 845.1983 -5.53 C35H40O24 16 
M11 methyl-monoCER glu-
curonide 
859.2094 859.2139 5.22 C36H42O24 16 
M12 dimethyl-monoHEG 537.1592 537.1603 1.99 C25H28O13 12 
M13 dimethyl-monoHER 683.2170 683.2182 1.72 C31H38O17 13 
M14 diHER 699.2129 699.2131 0.27 C31H38O18 13 
M15 triHER 743.2430 743.2393 -4.98 C33H42O19 13 
M16 methyl-diHER 713.2327 713.2288 -5.56 C32H40O18 13 
M17 dimethyl-diHER 727.2450 727.2444 -0.84 C33H42O18 13 
DBE, double bond equivalent. 
Impurities/metabolites 
Besides monoHER itself and monoHER metabolites, other compounds were also 
detected in bile, accounting for less than 0.5% of all compounds. On the basis of 
their mass spectral data, these compounds were identified as impurities of mo-
noHER, and metabolites of these impurities, i.e., diHER (M14), triHER (M15), 
methyl-diHER (M16), and dimethyl-diHER (M17). MonoHER was isolated from 
the hydroxyethylrutoside mixture Venoruton (consisting of monoHER, diHER, 
triHER, and tetraHER). Analysis of monoHER used in the present study con-
firmed the presence of diHER and triHER in very small amounts. 
C H A P T E R  6  
 100 
Time course of monoHER metabolite formation
As shown in Figure 3, the concentrations of most metabolites peaked at 60 min 
after monoHER administration. Exceptions are t
disaccharide has been hydrolyzed, i.e., the glucosides methyl
and dimethyl-monoHEG (M12). They ar
min after monoHER administration their concentrations are higher than those 
of the other metabolites. 
 
Figure 3. Metabolic profile of monoHER in mice. At 0, 15, 60, 120, 180, and 240 min after an i
traperitoneal injection of monoHER (500 mg/kg), bile was collected in three mice and analyzed for 
the presence of monoHER metabolites. Panel A shows all detected monoHER metabolites. In panel 
B, the two compounds present in highest concentration (P and M5)
visualize metabolites in the lower concentration range.
micromolar monoHER equivalents. The S.D. was max
of the different metabolites was achieved by their UV response at 355 nm. 
 
he metabolites in which the 
-monoHEG (M9) 
e gradually formed over time, and 240 
 
n-
 are not shown, to more clearly 
The mean concentrations are expressed as 
imally 10% for all metabolites. Quantification 
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Discussion  
The main objective of the present study was to completely characterize the 
metabolites of the semisynthetic antioxidant flavonoid monoHER in mice. Be-
cause the liver is the main drug-eliminating organ, characterization was done in 
the bile fluid of mice. Our results show that monoHER is extensively metabo-
lized. A scheme of the identified metabolites is shown in Figure 4. The observed 
routes of monoHER metabolism are methylation, glucuronidation, oxidation of 
its hydroxyethyl group, GSH conjugation, and hydrolysis of its disaccharide. 
The primary metabolic route appeared to be methylation, yielding a 4’-O-
methylated metabolite of monoHER (M5) that represents approximately 40% of 
all detected compounds. The O-methylation of catechols is mainly catalyzed by 
the enzyme COMT (Zhu, 2002). It has been shown that methylation of flavon-
oids makes them more lipophilic, thereby improving their transport over bio-
logical membranes and increasing their cellular uptake (Spencer et al., 2004; 
Spencer et al., 2003). Moreover, blocking the free hydroxyl group by methyla-
tion prevents other conjugation reactions such as glucuronidation at this group 
and thus increases the metabolic stability of flavonoids (Walle, 2009). Methyla-
tion of the hydroxyl group also decreases the antioxidant capacity of flavonoids 
(Spencer et al., 2003). However, this decreased activity is compensated for by 
their increased intracellular concentration and metabolic stability (Spencer et 
al., 2003). Moreover, after their uptake into the cells, cytochrome P450-
dependent demethylation can take place, thereby generating the parent com-
pound (Breinholt et al., 2002). In addition, their high concentration formed and 
their relatively slow elimination suggests that the O-methylated metabolites of 
monoHER contribute to the antioxidant effect of monoHER.  
Several hours after monoHER administration, the glucosides methyl-
monoHEG (M9) and dimethyl-monoHEG (M12) have the highest concentrations 
of all metabolites. In addition to methylation, the rhamnose sugar has been 
removed in these metabolites. The time course of their formation indicates that 
they are primarily formed out of methyl-monoHER (M5) (Figure 3). These me-
tabolites contain a terminal glucose moiety. Flavonoid glucosides are suggested 
to enter cardiac cells via the glucose transporter 4 (Passamonti et al., 2009; 
Strobel et al., 2005), which transports glucose in the heart (Huang and Czech, 
2007). Because cellular access is required to exert a protective effect, the me-
thylated metabolites of monoHER as well as the monoHER glucosides are be-
lieved to contribute to the protective effect of monoHER.  
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Figure 4. Proposed metabolism of monoHER in mice. The percentages in parentheses indicate the 
relative amounts of each metabolite. The relative amounts of the metabolites were estimated by 
calculating the AUC from the concentration-time curve of each metabolite, using the trapezoidal 
rule, and expressing this as a percentage of the total AUC of all detected compounds together. 
 
The monoHER metabolites formed out of the other three conjugation reactions, 
i.e., glucuronidation, GSH conjugation, and oxidation, are charged at physiologi-
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cal pH. These metabolites therefore probably have decreased cellular uptake 
and are unlikely to be involved in the protective effect of monoHER. In addition, 
Spencer et al. (2003) reported that the glucuronidated metabolites of flavono-
ids are unable to protect against oxidative stress-induced damage, presumably 
because of their inability to enter cells. The presence of GSH-monoHER conju-
gates indicates that monoHER has functioned as an antioxidant. GSH-monoHER 
formation is preceded by the oxidation of the catechol of monoHER, e.g., when 
it acts as an antioxidant by scavenging free radicals. Relatively low amounts of 
the GSH-monoHER conjugate were found, probably because there was no oxid-
ative stress in these mice and because, as recently shown, the monoHER qui-
none reacts with the antioxidant ascorbate rather than with GSH (Jacobs et al., 
2010).  
To summarize, it has been observed that even though monoHER is practi-
cally cleared from the body at the time that doxorubicin concentrations are still 
relatively high, the antioxidant monoHER does protect against doxorubicin-
induced cardiotoxicity in mice (van Acker et al., 2000). Three possible explana-
tions can be given for this prolonged protective effect: first, it could mean that 
to have a protective effect monoHER only has to be present when the doxoru-
bicin concentration peaks, i.e., shortly after doxorubicin administration; second, 
monoHER could have a “memory effect” on cells by inducing a protection that 
lasts after monoHER has been cleared from the body; or third, as the results of 
the present study suggest, monoHER metabolites might contribute to the ob-
served cardioprotective effects. Although further research is needed, the me-
thylated metabolites and the glucosides in particular are expected to contribute 
to the antioxidant activity of monoHER, which is involved in its protective effect 
against doxorubicin-induced cardiotoxicity. 
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Abstract 
Despite its well-known cardiotoxicity, the anthracycline doxorubicin continues 
to be a widely used chemotherapeutic agent. The antioxidant flavonoid 7-
mono-O-(β-hydroxyethyl)-rutoside (monoHER) showed protection against dox-
orubicin-induced cardiotoxicity in mice. This protection could however not be 
observed in humans. A possible explanation for this different effect in mice and 
humans may be a difference in monoHER metabolism between both species. 
This prompted us to investigate the metabolism of monoHER in humans and to 
compare this with its metabolism in mice. Five healthy volunteers received mo-
noHER by intravenous infusion. Up to three hours after infusion bile fluid was 
collected in which monoHER metabolites were identified by LC-DAD-TOF-MS 
and 
1
H NMR. Thirteen different metabolites could be identified. The observed 
routes of monoHER metabolism were glucuronidation, methylation, oxidation 
of its hydroxyethyl group, GSH conjugation, and hydrolysis of its disaccharide 
group. In mice the major metabolic route appeared to be methylation, thereby 
forming bioactive metabolites that are implicated in the cardioprotective effect 
of monoHER. In humans monoHER is predominantly converted into inactive 
glucuronidated metabolites. Our data indicate that the different pharmacologi-
cal effect of monoHER in mice and men might be explained by a difference in 
monoHER metabolism between both species. This study adds to the growing 
appreciation of flavonoid metabolites as bioactive compounds. 
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Introduction 
Doxorubicin is a very effective antitumour agent, widely applied in the treat-
ment of various types of cancer. Unfortunately, treatment with doxorubicin is 
limited by a cumulative dose-dependent cardiotoxicity, which manifests itself as 
congestive heart failure (Bast et al., 2007; Lipshultz et al., 2005; Singal and 
Iliskovic, 1998). Doxorubicin-induced cardiotoxicity mainly results from free 
radicals, which are produced during redox-cycling of doxorubicin (Horenstein et 
al., 2000; Xu et al., 2001). Cardiac tissue is particularly vulnerable to free radical-
induced injury because antioxidant enzymes such as superoxide dismutase and 
catalase, which protect against oxidative damage, are markedly reduced com-
pared with other tissues in the body (Doroshow et al., 1980; Iarussi et al., 2000; 
Julicher et al., 1988). 
Flavonoids can be considered as potential protectors against doxorubicin-
induced cardiotoxicity because of their excellent radical scavenging properties 
(Amic et al., 2007; Rice-Evans et al., 1996; van Acker et al., 1995; van Acker et 
al., 1996). In a series of structurally related flavonoids, the semisynthetic fla-
vonoid 7-mono-O-(β-hydroxyethyl)-rutoside (monoHER, Figure 1), which is a 
constituent of the registered drug Venoruton, was found to be the most potent 
antioxidant (Haenen et al., 1993). 
 
 
Figure 1. Structural formula of monoHER and numbering of relevant carbon atoms. 
 
Preclinical experiments in mice have shown that monoHER effectively protects 
against doxorubicin-induced cardiotoxicity, without interfering with the antitu-
mour activity of doxorubicin (van Acker et al., 2000; van Acker et al., 1997). 
Recent experiments revealed that monoHER metabolites are likely to contribute 
to these cardioprotective effects in mice (Jacobs et al., 2011b). On the basis of 
their time course of formation and chemical characteristics, especially the me-
thylated metabolites and the monoHER glucosides seem to be involved in the 
protective effect of monoHER (Jacobs et al., 2011b). In a clinical phase II trial 
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with metastatic cancer patients, monoHER did not significantly protect against 
the cardiotoxicity induced by doxorubicin (Bruynzeel et al., 2007). It can be 
excluded that this difference between mice and humans is due to a difference 
in monoHER levels because the pharmacokinetic end points (Cmax and AUC
∞
) of 
monoHER were similar in both species (Abou El Hassan et al., 2003; Willems et 
al., 2006). Therefore, to explain the different pharmacological effect of monoH-
ER in humans and mice, we hypothesized that metabolites of monoHER, which 
contribute to its cardioprotection, are formed in mice but not (or to a lesser 
extend) in humans. 
The objective of the present study was to characterize the metabolites of 
monoHER in humans and compare the identified metabolites with those previ-
ously found in mice. Our data show that there is a difference in the metabolism 
of monoHER between men and mice, which might explain the different phar-
macological effect of monoHER in both species. 
Materials and methods 
Chemicals 
7-Mono-O-(β-hydroxyethyl)-rutoside (monoHER) was provided by Novartis Con-
sumer Health (Nyon, Switzerland). 2’-GSH-monoHER and 4’-methyl-monoHER 
were synthesized as described previously (Jacobs et al., 2011b; Jacobs et al., 
2009). β-Glucuronidase from Helix pomatia (type H-5), sulphatase from Helix 
pomatia (type H-1), trifluoroacetic acid (TFA), deuterated water (D2O) and so-
dium acetate were purchased from Sigma-Aldrich (Steinheim, Germany). Ace-
tonitrile HPLC grade, methanol and dimethyl sulfoxide (DMSO) were obtained 
from Biosolve (Valkenswaard, The Netherlands).  
Study population 
Five healthy volunteers (three men and two women) with a mean age of 34 
years took part in this study. Exclusion criteria were: diagnosed hepatic diseases 
like chronic hepatitis B and C, gallstones disease and bile excretion disturbances 
like Primary Biliary Cirrhosis and Primary Sclerosing Cholangitis, fat storage dis-
ease like non-alcoholic steatohepatitis (NASH), use of any medication (except 
oral anticonception), consumption of 4 or more glasses of alcohol per day. Be-
fore the start of the study, blood was taken to verify adequate liver function. 
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Ethical Considerations 
This study was approved by the Medical Ethical Review Committee of the Uni-
versity Hospital Gasthuisberg (Leuven, Belgium). The outline of the study was 
explained to the volunteers before obtaining their written informed consent.  
Treatment 
Formulation of the drug 
The monoHER infusion was formulated under aseptic conditions by the De-
partment of Pharmacy, University Hospital Gasthuisberg, Leuven, Belgium. The 
required amount of monoHER was dissolved in 100 ml 5% dextrose for intra-
venous use, adjusted to pH 9.3 using 4 M sodium hydroxide. After dissolution of 
the drug, the solution was readjusted to pH 8.4 with 1 M hydrochloric acid. The 
final solution was filtered through a 0.2-µm filter. The solution is chemically 
stable for at least 24 hour at room temperature (Abou El Hassan et al., 2000) 
and therefore the volunteers received the drug within 24 h after preparation. 
Administration of the drug 
MonoHER was administered as an intravenous infusion for 15 minutes at a dose 
of 1500 mg/m
2
. 
Bile aspiration 
Before monoHER infusion and every 10 minutes over a period of 3 hours after 
the start of monoHER infusion, bile fluid from the healthy volunteers was col-
lected via oral intubation of a tube with a balloon, which was maneuvered into 
the second part of the duodenum under fluoroscopic control (Koek et al., 2004). 
The balloon served to prevent mixing of gastric contents or food with duodenal 
contents. After the balloon was inflated with air, a high caloric drink (200 ml 
Nutridrink®; 300 Kcal: 13% proteins, 48% carbohydrates and 39% lipids. Nutri-
cia, Belgium) was given to stimulate bile excretion. At each time-point, the aspi-
ration was performed until about 10 ml was collected. The bile fluid was divided 
into portions of 1 ml and frozen at -80°C. 
Blood sampling 
Venous blood samples (10 ml) were collected from the healthy volunteers just 
before monoHER infusion (blank) and 30, 45, 60, and 120 minutes after the 
start of monoHER infusion. Blood was collected in a sodium heparin-containing 
glass tube. Blood cells were spun down in a centrifuge at 4000 rpm for 5 mi-
nutes. Aliquots of 1 ml plasma (supernatant) were transferred into polypropy-
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lene micro-test tubes. Each sample was frozen immediately at -80°C until analy-
sis.  
Sample preparation 
Samples of bile fluid or plasma were mixed with twice the volume of 
DMSO/methanol (1/4, v/v). The mixture was vortexed and centrifuged (17060 g, 
15 min). The supernatant was collected and injected onto the LC column.  
To identify the presence of glucuronide and sulphate conjugates in the bile 
fluid, β-glucuronidase solution (40 U in 0.1 M sodium acetate pH 4.0) and sul-
phatase solution (40 U in 0.1 M sodium acetate pH 6.2) were respectively added 
to a sample of bile fluid. Incubations were carried out for 30 minutes at 37°C, 
which provides maximal deconjugation (cleavage of ether-bonds of glucuron-
ides and sulphates, respectively) (Bartholome et al., 2010). Following incuba-
tion, the samples were extracted as described above and analyzed by LC-DAD. 
Bile samples were also spiked with reference compounds (monoHER, 2’-
GSH-monoHER, and 4’-methyl-monoHER) to examine the possible presence of 
these compounds in the bile fluid. 
LC-DAD analysis 
LC-DAD of the bile and plasma samples was performed on an Agilent 1100 se-
ries LC-DAD system (Agilent Technologies, Santa Clara, CA, USA). Analytical se-
parations were achieved using an ODS-3 column (5 μm, 250 x 3 mm) (Inertsil; 
Varian Inc., Palo Alto, CA, USA) at 40°C. The mobile phase consisted of ultra-
pure water containing 0.1% (v/v) TFA (mobile phase A) and acetonitrile contain-
ing 0.1% (v/v) TFA (mobile phase B). The gradient was started at t = 0 min with 
15% (v/v) B, was changed linearly over the first 20 min to 30% (v/v) B followed 
by an increase to 90% (v/v) B at t = 25 min, and was then stationary for 1 min. 
The column was reequilibrated with 15% (v/v) B for 5 min. A flow rate of 1 
ml/min and
 
an injection volume of 10 µl were used. Detection was performed 
with a diode array detector (DAD). The chromatograms presented are based on 
detection at 355 nm. The LC-DAD system was controlled using ChemStation 
software (A09.03, Agilent). 
LC-DAD-TOF-MS analysis 
LC-DAD-TOF-MS, including fragmentation and exact mass measurements, was 
performed using an Agilent 1100 LC-DAD-TOF-MS system (Agilent Technologies) 
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to further characterize the peaks in the LC chromatogram. The UV signal at 355 
nm was collected. Electrospray ionization (ESI) was performed in positive mode 
with the following conditions: m/z range 50 to 3000, 175 V fragmentor (varied 
for fragmentation experiments), 0.1 m/z step size, 1.013 cycles/s, 350°C drying 
gas temperature, 10 liters of N2/min drying gas, 35 psig nebulizer pressure, and 
2 kV capillary voltage. The MS data were collected using internal reference mass 
correction. The reference substances [purine at 121.050873 Da and hexakis-
(1H,1H,3H-tetrafluoro-pentoxy)phosphazene (HP-921) at 922.009798 Da] were 
continuously injected into the electrospray ion source equipped with a dual-
sprayer mechanism. The LC conditions were the same as described above. The 
LC-DAD-TOF-MS system was controlled using MassHunter qualitative analysis 
software (B03.01; Agilent Technologies).  
Elemental composition calculations from the exact masses were performed 
off-line using MassHunter. This software was used to work with the MS spec-
trum manually generated for every peak. Potential assignments were calculated 
using the monoisotopic masses with specifications of a tolerance of 10 ppm 
deviation. The number and types of expected atoms were set as follows: car-
bons <60, hydrogens <120, oxygens <30, nitrogens <30, and sulfurs <5, whereas 
the double bond equivalent (DBE) was set to <50. 
Preparative high-performance liquid chromatography 
Preparative HPLC was carried out on a Gilson system (Gilson Inc., Middleton, 
WI, USA), which comprised a pump (model 305), a manometric module (model 
806), a dynamic mixer (model 811B) and a UV detector (Water 2487). The de-
tection wavelength was 355 nm. A Zorbax SB C18 column (21.2 x 250 mm) (Agi-
lent) was used with a mobile phase of (A) H2O and (B) acetonitrile, both contain-
ing 0.1% TFA. The gradient was started at t = 0 min with 20% (v/v) B, changed 
linearly over 26 min to 90% (v/v) B and was stationary for 4 min. The column 
was reequilibrated with 20% acetonitrile for 5 min. The flow rate was 20 ml/min 
and the injection volume 600 µl. 
1
H NMR measurements 
1
H NMR measurements were performed in D2O at 25 °C on a Bruker Avance 300 
MHz NMR equipped with a 5-mm QNP probe (Varian, Mulgrave Victoria, Aus-
tralia). A 10 s scan time and a 54 min acquisition time were used. Chemical 
shifts are reported in ppm relative to tetramethylsilane. The results were con-
firmed by the software program ACD/HNMR Predictor (version 8.09). 
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Quantification of monoHER metabolites 
Bile and plasma concentrations of the different metabolites were determined 
by their UV response at 355 nm (area of the peak in the chromatogram). Be-
cause no commercial reference standards were available for these metabolites, 
it was assumed that the UV response at 355 nm is equal to that of monoHER for 
all metabolites. This is a reasonable assumption because they all have the same 
chromophore and the UV spectra in the 355 nm region of all metabolites are 
similar to that of monoHER.  
The relative amounts of the metabolites were estimated by calculating the 
area under the curve (AUC) from the concentration-time curve of each metabo-
lite, using the trapezoidal rule, and expressing this as percentage of the total 
AUC of all detected compounds together. 
Results 
Metabolites in bile 
Representative LC chromatograms of bile samples, collected from the healthy 
volunteers before the start of monoHER infusion (blank bile) and 65 min after 
i.v. administration of 1500 mg/m
2
 monoHER, are shown in Figure 2. 
The chromatogram of bile collected after monoHER administration shows 
several additional peaks compared with that of the blank bile. The DAD spectra 
of these peaks and the absorption maxima at 355 nm are similar to those of 
monoHER, indicating that these peaks correspond to metabolites of monoHER. 
Six major metabolites (M1-M6), representing more than 90% of all detected 
compounds, and seven minor metabolites (M7-M13) were detected. Also other 
compounds that could be traced as impurities of monoHER and their metabo-
lites (M14-M18) were detected in bile, accounting for less than 1% of all com-
pounds. 
Metabolites in plasma 
In the plasma samples collected from the healthy volunteers after monoHER 
infusion, analyzed by LC-DAD, the parent compound monoHER (96.5%) and 
three major metabolites M2 (2%), M3 (0.5%) and M5 (1.0%) could be detected. 
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Figure 2. Representative LC chromatogram of (A) bile collected from a human volunteer just be-
fore monoHER administration and (B) bile collected from the same volunteer 65 min after i.v. 
administration of monoHER. The numbered peaks represent monoHER [parent(P)] and its six major 
metabolites (M1-M6). The chromatograms presented are based on detection at 355 nm. 
Identification of metabolites 
Tandem mass spectrometry fragmentation of the parent compound produced 
three key fragments: m/z 509 (- 145, loss of rhamnose sugar), m/z 347 (- 307, 
loss of rhamnose and glucose sugar), and m/z 303 (- 351, loss of rhamnose, 
glucose, and the hydroxyethyl group of the A ring) (Figure 3). 
Identification of the different metabolites was done based on their mass-to-
charge ratio (m/z) values, mass change from the parent compound, main frag-
ment ions, and elemental composition (obtained by accurate mass measure-
ments). Further details about the identification of the metabolites have been 
published previously (Jacobs et al., 2011b). The results are summarized in Table 
1 and Table 2. The four major metabolites (M2, M3, M5 and M6) were collected 
by preparative HPLC and further characterized by 
1
H NMR (Table 3). An over-
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view of the chemical structures of the metabolites and their mutual relation-
ships are given in Figure 4. 
 
Figure 3. Mass spectrum of monoHER obtained by tandem mass spectrometry, and the proposed 
origin of the key fragment ions.  
 
Table 1. MonoHER and its metabolites identified in bile of the volunteers by LC-DAD-TOF-MS. 
 tR 
(min) 
Compound [M+H]
+
 
(m/z) 
Mass change 
from parent 
Main fragment ions (m/z) 
  Parent compound    
P 8.5 monoHER 655 0 509, 347, 303 
  Major metabolites    
M1 5.6 monoHER glucuronide 831 + 176 765, 685, 523, 347, 303 
M2 6.3 monoHER glucuronide 831 + 176 765, 685, 523, 347, 303 
M3 6.9 methyl-monoHER glucuronide 845 + 190 699, 537, 361, 317 
M4 9.7 monoCER 669 + 14 523, 463, 361 
M5 11.1 methyl-monoHER 669 + 14 523, 361, 317 
M6 12.3 methyl-monoCER 683 + 28 537, 375 
  Minor metabolites    
M7 3.4 GSH-monoHER 960 + 305 814, 705, 652, 523, 371 
M8 7.1 monoHER diglucuronide 1007 + 352 861, 845, 831, 699, 523, 347 
M9 7.6 methyl-monoHEG 523 - 132 479, 361, 303 
M10 7.8 monoCER glucuronide 845 + 190 537, 361 
M11 8.8 methyl-monoCER glucuronide 859 + 204 551, 375 
M12 12.5 dimethyl-monoHEG 537 - 118 375 
M13 14.8 dimethyl-monoHER 683 + 28 537, 375 
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  Impurities/metabolites    
M14 9.4 diHER 699 + 44 655, 523, 347 
M15 12.5 triHER 743 + 88 622, 597, 435, 347 
M16 13.3 methyl-diHER 713 + 58 537, 361 
M17 14.8 dimethyl-diHER 727 + 72 537, 439, 361 
Abbreviations: HER = hydroxyethyl-rutoside, CER = carboxyethyl-rutoside, HEG = hydroxyethyl-
glucoside. 
 
Table 2. Exact mass determinations (TOF-MS)  
 Compound Measured m/z 
([M+H]
+
) 
Calculated m/z 
([M+H]
+
) 
Error 
(ppm) 
Elemental 
composition 
DBE 
P monoHER 655.1872 655.1869 -0.6 C29H34O17 13 
M1/M2 monoHER glucuronide 831.2161 831.2189 3.41 C35H42O23 15 
M3 methyl-monoHER glu-
curonide 
845.2352 845.2346 -0.73 C36H44O23 15 
M4 monoCER 669.1684 669.1661 -3.41 C29H32O18 14 
M5 methyl-monoHER 669.2028 669.2025 -0.38 C30H36O17 13 
M6 methyl-monoCER 683.1838 683.1818 -2.97 C30H34O18 14 
M7 GSH-monoHER 960.2537 960.2551 1.39 C39H49N3O23S1 17 
M8 monoHER diglucuronide 1007.2520 1007.2510 -1.04 C41H50O29 17 
M9 methyl-monoHEG 523.1457 523.1446 -2.07 C24H26O13 12 
M10 monoCER glucuronide 845.2029 845.1983 -5.53 C35H40O24 16 
M11 methyl-monoCER glu-
curonide 
859.2094 859.2139 5.22 C36H42O24 16 
M12 dimethyl-monoHEG 537.1592 537.1603 1.99 C25H28O13 12 
M13 dimethyl-monoHER 683.2170 683.2182 1.72 C31H38O17 13 
M14 diHER 699.2129 699.2131 0.27 C31H38O18 13 
M15 triHER 743.2430 743.2393 -4.98 C33H42O19 13 
M16 methyl-diHER 713.2327 713.2288 -5.56 C32H40O18 13 
M17 dimethyl-diHER 727.2450 727.2444 -0.84 C33H42O18 13 
Abbreviations: HER = hydroxyethyl-rutoside, CER = carboxyethyl-rutoside, HEG = hydroxyethyl-
glucoside, DBE = double bond equivalent. 
 
 
 
 
 
 
 
.
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Table 3. 
1
H NMR characteristics of monoHER and its main metabolites identified in human bile. 
 Compound Proton Chemical shift (ppm) Multiplicity Number of protons 
P monoHER H2’ 
H6’ 
H5’ 
H6 
H8 
OH5 
CH2CH2O7 
Gluc-H1 
Methyl 
7.45 
7.49 
6.79 
6.22 
6.47 
4.32 
3.66 
- 
- 
B 
B 
D 
D 
D 
S 
T 
- 
- 
1 
1 
1 
1 
1 
1 
4 
- 
- 
M2 monoHER-3’-
glucuronide 
H2’ 
H6’ 
H5’ 
H6 
H8 
OH5 
CH2CH2O7 
Gluc-H1 
Methyl 
7.59 
7.59 
6.84 
6.13 
6.22 
4.39 
3.66 
5.05 
- 
B 
B 
D 
S 
S 
S 
T 
D 
- 
1 
1 
1 
1 
1 
1 
4 
1 
- 
M3 3’-methyl-monoHER-4’-
glucuronide 
H2’ 
H6’ 
H5’ 
H6 
H8 
OH5 
CH2CH2O7 
Gluc-H1 
Methyl 
7.50 
7.64 
6.90 
6.15 
6.28 
4.34 
3.66 
5.10 
3.85 
S 
D 
D 
S 
S 
S 
T 
D 
S 
1 
1 
1 
1 
1 
1 
4 
1 
3 
M5 4’-methyl-monoHER H2’ 
H6’ 
H5’ 
H6 
H8 
OH5 
CH2CH2O7 
Gluc-H1 
Methyl 
7.52 
7.60 
6.98 
6.30 
6.57 
4.37 
3.70 
- 
3.77 
D 
DD 
D 
D 
D 
S 
T 
- 
S 
1 
1 
1 
1 
1 
1 
4 
- 
3 
M6 4’-methyl-monoCER H2’ 
H6’ 
H5’ 
H6 
H8 
OH5 
CH2CH2O7 
Gluc-H1 
Methyl 
7.67 
7.72 
7.08 
6.26 
6.51 
4.51 
- 
- 
3.86 
S 
D 
D 
S 
S 
S 
- 
- 
S 
1 
1 
1 
1 
1 
1 
- 
- 
3 
Abbreviations: S = singlet, D = doublet, DD = double doublet, T = triplet, B = Broad. 
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Figure 4. Proposed metabolism of monoHER in humans. The percentages in parentheses indicate 
the relative amounts of each metabolite. The relative amounts of the metabolites were estimated 
by calculating the AUC from the concentration-time curve of each metabolite, using the trapezoi-
dal rule, and expressing this as a percentage of the total AUC of all detected compounds together. 
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Concentration-time profiles 
Figure 5 shows the concentrations of the p
lite in bile at different time points after monoHER administration. From this 
figure it can be seen that monoHER is rapidly metabolized. The major metabolic 
pathway is glucuronidation. Incubation of bile with the enzyme 
glucuronidase, which cleaves the ether bond between glucuronic acid and the 
parent compound, caused the peaks of the glucuronide metabolites in the 
chromatogram to disappear with a concomitant increase in the area of the m
noHER peak (data not shown). Other ob
are methylation, oxidation of its hydroxyethyl group, GSH conjugation, and 
hydrolysis of its disaccharide. 
Comparison of the relative amounts of the different metabolites reveals 
that both monoHER glucuronide (M2) and th
ER glucuronide (M3) are the major metabolites, accounting for 26
the total amount of all detected compounds, respectively. The relative amounts 
of all detected compounds, compared with those in mice, are presented
ble 4. 
Figure 5. Metabolic profile of monoHER in humans. Every 10 min
tion (1500 mg/m
2
, i.v.), bile was collected and analyzed for the presence of monoHER metabolites. 
The concentrations are expressed as micromolar 
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Discussion 
The results of this study suggest that the different pharmacological effect of 
monoHER in mice and humans may originate from a difference in monoHER 
metabolism between the two species. We characterized the metabolites of 
monoHER that are formed in humans and compared them with those previously 
found in mice. Because the liver is the main drug-eliminating organ characteri-
zation was done in the bile fluid of healthy volunteers who received monoHER 
by intravenous infusion. This appeared to be a successful strategy because we 
were able to identify up to thirteen different metabolites.  
In humans, the same metabolites were found as in mice (Jacobs et al., 
2011b). However, in mice especially methylation was detected, while in humans 
mainly glucuronidation was observed (Table 4). Other observed metabolic reac-
tions were oxidation, GSH conjugation, and hydrolysis of the disaccharide.  
 
Table 4. Relative amount of each monoHER metabolite (% of total) detected in bile of humans and 
mice.  
 Compound Humans Mice 
 Parent compound   
P monoHER 5.8 ± 2.3 29.2 ± 4.0 
 Major metabolites
a
   
M1 monoHER glucuronide 5.4 ± 1.1 6.3 ± 0.4 
M2 monoHER glucuronide 26.4 ± 5.2 4.7 ± 0.2 
M3 methyl-monoHER glucuronide 34.2 ± 6.3 8.6 ± 0.3 
M4 monoCER 2.6 ± 1.8 2.1 ± 0.1 
M5 methyl-monoHER 14.8 ± 3.2 39.9 ± 1.4 
M6 methyl-monoCER 7.6 ± 3.4 5.4 ± 1.2 
 Minor metabolites
b
   
M7 GSH-monoHER 0.06  0.56 
M8 monoHER diglucuronide 0.93 0.67 
M9 methyl-monoHEG 0.44 0.86 
M10 monoCER glucuronide 0.52 0.32 
M11 methyl-monoCER glucuronide 1.07 0.35 
M12 dimethyl-monoHEG 0.04  0.56 
M13 dimethyl-monoHER 0.14 0.48 
a
 Quantification with LC-DAD (mean ± S.D., humans: n = 5, mice: n = 3). 
b 
Quantification with LC-MS based on one AUC of each compound. 
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For other flavonoids also sulfation has been described, however no sulphates 
were detected for monoHER. This is probably because a relatively high dose (~ 3 
gram) of monoHER was administered intravenously. At high doses the relative 
importance of sulfation decreases since this conjugation route becomes satu-
rated at a relative low concentration, which will result in a shift from sulfation 
toward glucuronidation (Koster et al., 1981). For other polyphenols, the limited 
data that are available on the proportions of the various types of conjugates 
indicate that the main metabolites in humans are glucuronides (Baba et al., 
2000; Doerge et al., 2000; Lee et al., 2002; Manach et al., 2003; Setchell et al., 
2001; Shelnutt et al., 2002; Zhang et al., 2003). 
Conjugation with glucuronic acid is mainly catalyzed by the liver enzyme 
uridine 5'-diphospho(UDP)-glucuronosyltransferase (UGT) (Radominska-Pandya 
et al., 1999). The resulting glucuronide is much more hydrophilic than the origi-
nal compound, making it unable to cross lipid membranes and enter cells (Min-
ers and Mackenzie, 1991). Therefore, the glucuronidated metabolites of mo-
noHER are unlikely to be involved in the cardioprotective effect of monoHER. In 
humans, the main metabolic route of monoHER appeared to be glucuronida-
tion, which might contribute to the absence of cardioprotection in humans. 
We were also able to detect GSH-monoHER conjugates. The presence of 
GSH conjugates indicates that monoHER has functioned as antioxidant. As a 
catechol, during the scavenging of reactive species, monoHER can be converted 
into a quinone and subsequently conjugate with glutathione (GSH) (Jacobs et 
al., 2009). Relatively low amounts of GSH-monoHER conjugate were found 
compared with the other metabolites, probably because there was no oxidative 
stress in the healthy volunteers and because, as recently shown, the monoHER 
quinone rather reacts with the antioxidant ascorbate than with GSH (Jacobs et 
al., 2010). Like the glucuronides and the oxidized metabolites, the GSH conju-
gates are charged at physiological pH, which will decrease their cellular uptake. 
Also taking into account the relatively low concentration of these metabolites, it 
is unlikely that these metabolites contribute to the protective effect of mono-
HER.  
Another metabolic route was methylation. The O-methylation of catechols 
is catalyzed by the enzyme catechol-O-methyltransferase (COMT) (Zhu, 2002). It 
has been shown that methylation makes flavonoids more lipophilic, thereby 
facilitating their transport over biological membranes and increasing their cellu-
lar uptake (Spencer et al., 2004; Spencer et al., 2003). Moreover, blocking the 
free hydroxyl group by methylation, prevents other conjugation reactions such 
as glucuronidation at this position, and thus increases the metabolic stability of 
flavonoids (Walle, 2009). It has been shown that the methylated metabolites of 
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the flavonoid quercetin provided significant protection against oxidative stress-
induced cellular damage (Spencer et al., 2003). Also the methylated metabolite 
of epicatechin, i.e. 3'-O-methylepicatechin, has been shown to exert protective 
effects (Spencer et al., 2001). In line with these findings, the methylated conju-
gates of monoHER are considered as active metabolites that contribute to the 
cardioprotective effect of monoHER. In contrast to humans, the major metabol-
ic pathway in mice is methylation. This might also explain why monoHER effi-
ciently protects the heart against doxorubicin-induced cardiotoxicity in mice 
and not in humans. 
The monoHER-glucosides are a group of compounds that might be of spe-
cial interest. These metabolites are formed by hydrolysis of the disaccharide, 
thereby removing the rhamnose sugar. They contain a terminal glucose moiety 
and are also methylated. Flavonoid glucosides are reported to rapidly enter 
cells via GLUT-transporters (Passamonti et al., 2009; Strobel et al., 2005), which 
also transport glucose (Huang and Czech, 2007). This will increase the intracellu-
lar antioxidant concentration and enhance their effect. The role of these meta-
bolites in the protective effect of monoHER needs to be further investigated. In 
mice, these metabolites are gradually formed over time and several hours after 
monoHER administration they have the highest concentrations compared with 
all other metabolites. This suggests that these metabolites might be of impor-
tance, particularly in the late protection against doxorubicin-induced cardiotox-
icity in mice. In humans, the concentration of these metabolites (M9 and M12) 
remains relatively low. 
Another remarkable finding in the clinical phase II study with monoHER was 
that monoHER enhances the antitumour activity of doxorubicin in certain types 
of cancer (Bruynzeel et al., 2007). This has not been observed in animals thus 
far (van Acker et al., 1997). It has been shown that monoHER sensitizes cancer 
cells to apoptosis by preventing doxorubicin-induced NF-κB activation (Jacobs et 
al., 2011a). The possible contribution of metabolites in this potentiating effect 
of monoHER has to be determined. 
To conclude, in humans monoHER is predominantly converted into inactive 
glucuronides. In mice, on the other hand, monoHER is mainly converted into an 
active metabolite, i.e methyl-monoHER. In addition, monoHER glucosides might 
be relevant. These metabolites are formed more extensively (especially at later 
time-points) in mice compared with humans. Thus, the difference in the meta-
bolic profile between men and mice might explain why the cardioprotective 
effect of monoHER in mice was not observed in humans. These results unders-
core that flavonoid metabolites are bioactive compounds that play a crucial role 
in the beneficial health effects of flavonoids. 
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Preclinical experiments have shown that the antioxidant flavonoid monoHER 
has several beneficial pharmacological actions (Chapter 1). One of its most im-
portant actions is that it protects the heart against doxorubicin-induced damage 
in mice. Unexpectedly, this protection could not clearly be observed in a clinical 
phase II study with metastatic cancer patients. In addition, the results of this 
clinical study suggest that monoHER enhances the antitumour activity of dox-
orubicin. The aim of this thesis was to explain these unexpected clinical find-
ings. This was done by further investigating the antioxidant properties of mo-
noHER and its interaction with endogenous antioxidants. Also the possible mo-
lecular mechanisms behind the antitumour effect of monoHER were studied. 
Moreover, to explain the different biological effects of monoHER in men and 
mice, the metabolism of monoHER was studied in both species and its metabo-
lites were characterized. 
Antioxidant function of monoHER 
During the scavenging of highly reactive species, antioxidants donate an elec-
tron or a hydrogen atom to the radical involved. In this way the reactivity of the 
radical is annihilated. However, in this reaction the antioxidant itself is con-
verted into an oxidation product that takes over part of the reactivity of the 
radical. In Chapter 2, it was shown that in the process of offering protection 
against free radicals, monoHER is likewise converted into a quinone. This mo-
noHER quinone is reactive towards thiols, e.g. it reacts with glutathione (GSH), 
thereby forming a GSH-monoHER adduct. Characterization of this adduct by MS 
and 
1
H NMR revealed that GSH binds to the C2’ position in the B ring of the 
monoHER quinone, identifying it as 2’-GSH-monoHER. Molecular quantum 
chemical calculations revealed that the C2’ of the monoHER quinone has the 
highest LUMO (lowest unoccupied molecular orbital) value, which underscores 
that the C2’ atom is most susceptible to nucleophilic attack by GSH. The GSH-
monoHER adduct could also be detected in the bile fluid of a healthy volunteer 
who received monoHER by intravenous infusion. To our knowledge we were the 
first to detect a GSH-flavonoid conjugate in vivo. The formation of the electro-
philic monoHER quinone is potentially harmful because when it reacts with GSH 
it might lower GSH levels and thus the antioxidant defense. In addition to the 
reaction with GSH, it is assumed that the quinone is also prone to react with e.g. 
essential thiol groups of proteins or enzymes, which might cause damage. Thus, 
the supposed beneficial effect of monoHER as an antioxidant could be eclipsed 
by the formation of quinone-like products with an electrophilic, toxic potential. 
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In Chapter 3 the reactivity of the 2’-GSH-monoHER adduct was studied and 
compared with that of the 6- or 8-GSH-quercetin adduct. It was found that GSH-
quercetin reacts with the thiol N-acetyl-L-cysteine (NAC) to form NAC-quercetin, 
whereas GSH-monoHER does not react with NAC. In addition, the adduct of the 
monoHER quinone with the dithiol dithiothreitol (DTT) is relatively stable, whe-
reas the DTT-quercetin adduct is readily converted into quercetin and DTT disul-
fide. These differences in reactivity of the thiol-flavonoid adducts demonstrate 
that GSH-monoHER is relatively stable, whereas GSH-quercetin is not. This dif-
ference in reactivity was corroborated by molecular quantum chemical calcula-
tions. Thus, although both flavonoid quinones are rapidly scavenged by GSH, 
the advantage of monoHER is that it forms a stable conjugate with GSH, thereby 
preventing the possible spread of toxicity. These findings demonstrate that 
even structurally comparable flavonoids behave differently, which should be 
considered when evaluating the health effects of flavonoids. 
To prevent damage by reactive oxidation products of antioxidants, the hu-
man body has an intricate network of antioxidants that pass over the reactivity 
from one antioxidant to another in a controlled way, thereby gradually dimi-
nishing the reactivity of the radical and recycling the antioxidants. In Chapter 4, 
it was investigated how monoHER fits into this antioxidant network. This posi-
tion was compared with that of quercetin. Both the monoHER quinone and the 
quercetin quinone are reactive towards thiols of both GSH and proteins. How-
ever, in human blood plasma where GSH is practically absent, oxidized querce-
tin readily reacts with protein thiols, whereas oxidized monoHER does not react 
with plasma protein thiols. This could be explained by the presence of ascorbate 
in plasma, because ascorbate is able to reduce oxidized monoHER to the parent 
compound monoHER before oxidized monoHER can react with thiols. This is a 
major difference with oxidized quercetin that preferentially reacts with thiols 
rather than ascorbate (Boots et al., 2003). The difference in selectivity between 
monoHER and quercetin originates from an intrinsic difference in the chemical 
nature of their oxidation products, which was confirmed by molecular quantum 
chemical calculations. The reactivity is directed in different ways by the two 
flavonoids studied. The advantage of monoHER is that it can safely channel the 
reactivity of radicals into the antioxidant network where the reactivity is neutra-
lized. Thus, structurally related flavonoids belonging to the same subgroup and 
displaying a comparable radical scavenging activity, may have a different impact 
on health.  
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Antitumour effect of monoHER 
The results of the clinical phase II study, evaluating the protective effects of 
monoHER on doxorubicin-induced cardiotoxicity, suggest that monoHER en-
hances the antitumour activity of doxorubicin in soft tissue sarcomas. This ef-
fect was investigated in vitro using soft tissue sarcoma cell lines (Chapter 5). In 
one (WLS-160) of the four cell lines monoHER potentiated the antitumour activ-
ity of doxorubicin. In this cell line it appeared that the effect is mediated by the 
induction of an apoptotic pathway. Because monoHER is able to form a GSH-
monoHER adduct, it was investigated whether monoHER can deplete GSH in the 
soft tissue sarcoma cell lines. In contrast to the known GSH depleter L-
buthionine sulfoximine (BSO), monoHER did not significantly change GSH levels 
in these cancer cells. This suggests that the growth inhibitory effect of monoH-
ER in WLS-160 cells is not mediated via GSH depletion, which is in contrast to 
the GSH depletion observed in some cancer cells by some other flavonoids (Ka-
chadourian and Day, 2006; Kachadourian et al., 2007; Ramos and Aller, 2008). It 
is known that many chemotherapeutic agents induce the transcription factor 
NF-κB, which causes drug resistance in cancer cells (Sarkar and Li, 2008). Accor-
dingly, doxorubicin rapidly induced NF-κB activity in WLS-160 cells, which was 
prevented by monoHER. Thus, down-regulation of NF-κB activation by monoH-
ER may be responsible for the sensitization of these cancer cells to doxorubicin. 
From this study it may be assumed that monoHER might improve chemothera-
py for certain soft tissue sarcoma patients. Moreover, it cannot be excluded 
that monoHER may also be valuable for the treatment of other tumours that 
have developed resistance through NF-κB activation. 
Metabolism of monoHER in mice and men 
In mice, monoHER has been successfully used as a protector against doxorubi-
cin-induced cardiotoxicity. However, most monoHER has already been cleared 
from the body at the time that doxorubicin concentrations are still high. This 
suggests that not only the parent compound monoHER itself, but also monoHER 
metabolites could be responsible for the observed cardioprotective effects in 
mice. In Chapter 6, the metabolism of monoHER was investigated in the bile 
fluid of mice. This led to the characterization of thirteen different metabolites. 
The observed routes of monoHER metabolism were methylation, glucuronida-
tion, oxidation of its hydroxyethyl group, GSH conjugation, and hydrolysis of its 
disaccharide. In line with other flavonoids, methylated monoHER and the mo-
noHER glucosides were expected to have a relatively high cellular uptake and a 
low clearance from the body. Therefore, it is suggestive that these metabolites 
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might contribute to the observed protection of monoHER against doxorubicin-
induced cardiotoxicity. 
The observed preclinical protection of monoHER against doxorubicin-
induced cardiotoxicity in mice could however not be observed in the clinical 
phase II study with metastatic cancer patients (Bruynzeel et al., 2007). It could 
be that metabolites of monoHER, which contribute to its cardioprotection, are 
formed in mice but not (or to a lesser extend) in men. Therefore, the metabol-
ism of monoHER was also investigated in the bile fluid of healthy volunteers 
(Chapter 7). The same metabolites were found in men as previously in mice; 
however the relative amounts of the metabolites were quite different. The 
major metabolic route in mice appeared to be methylation while in humans 
especially glucuronidation was observed. It has been shown that methylation of 
flavonoids makes them more lipophilic, thereby improving their transport over 
biological membranes and increasing their cellular uptake (Spencer et al., 2004; 
Spencer et al., 2003). It is therefore suggestive that the methylated conjugates 
of monoHER are active metabolites that contribute to the observed cardiopro-
tective effect of monoHER in mice. Glucuronidation, on the other hand, leads to 
reduced cellular uptake and accelerated elimination (Miners and Mackenzie, 
1991) and thus does not contribute to the cardioprotective effect of monoHER. 
Moreover in mice, in contrast to men, monoHER metabolites in which the dis-
accharide is cleaved -and thus contain a free glucose moiety- were formed at 
later time-points and to a greater extend. These metabolites are possibly taken 
up by cardiac cells via glucose transporters, thereby increasing the intracellular 
antioxidant concentration and contributing to the protective effect of monoH-
ER. From this study it could be concluded that the difference in the metabolic 
profile between men and mice might possibly explain the different biological 
activity of monoHER in both species. 
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Implications and further research 
MonoHER and its metabolites are good candidates for further investigations. 
Besides the favourable properties of monoHER described in the introductory 
chapter, the research described in this thesis added some more advantages, i.e., 
the oxidation product of monoHER (in contrast to that of quercetin) can more 
easily be reduced to monoHER and is therefore relatively harmless, monoHER 
can reduce NF-κB activation in certain tumour cells, and certain monoHER me-
tabolites may contribute to cardioprotection and possibly to antitumour activi-
ty. 
Therefore, several interesting research lines are open for the future: 
• Concerning the antitumour properties of monoHER, it would be interesting 
to investigate whether monoHER also sensitises other tumours that have 
developed resistance to chemotherapy through NF-κB activation. 
• It would also be valuable to study the antioxidant and antitumour activities 
of the newly identified monoHER metabolites.  
• Promising active metabolites can then be further investigated in a tumour 
bearing nude mouse model. 
• Because it is likely that the methylated metabolites of monoHER contribute 
to its cardioprotective effects, it would be interesting to measure their ef-
fects in our mouse atrium model and to measure the pharmacokinetics of 
the active metabolites in plasma and heart tissue of mice. 
• In a next step, the cardioprotective metabolites have to be investigated in 
mice. 
• If results are promising, clinical study/studies may be proposed regarding 
the antitumour and/or cardioprotective effect. 
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Uit preklinische experimenten is gebleken dat het antioxidant flavonoïde mo-
noHER verschillende gunstige farmacologische eigenschappen bezit (Hoofdstuk 
1). Eén opmerkelijke eigenschap is de bescherming tegen doxorubicine geïndu-
ceerde hartschade in muizen. Deze bescherming kon helaas niet duidelijk wor-
den bevestigd in een klinische fase II studie met een kleine groep kankerpatiën-
ten met een metastatische ziekte. De resultaten van deze klinische studie sug-
gereerden wel dat monoHER de antitumor activiteit van doxorubicine versterkt. 
Het doel van dit proefschrift was om deze onverwachte klinische bevindingen 
nader te verklaren. Hiertoe werden de antioxidant eigenschappen van mono-
HER en de interactie met endogene antioxidanten nader bestudeerd. Ook wer-
den de mogelijke moleculaire mechanismen achter het gunstige effect van mo-
noHER op de antitumor werking van doxorubicine onderzocht. Om de verschil-
lende biologische effecten van monoHER in muis en mens te verklaren, werd 
bovendien het metabolisme van monoHER in zowel muis als mens bestudeerd 
en werden de monoHER metabolieten gekarakteriseerd. 
Antioxidant func ie van monoHER 
Tijdens het wegvangen van reactieve deeltjes (radicalen) doneren antioxidanten 
een elektron of een waterstofatoom aan het betrokken radicaal. Op deze ma-
nier wordt de reactiviteit van het radicaal tenietgedaan. Tijdens deze reactie 
wordt het antioxidant echter zelf omgezet in een oxidatieproduct, dat een deel 
van de reactiviteit van het radicaal overneemt. In Hoofdstuk 2 werd aange-
toond dat monoHER ook wordt omgezet in een oxidatieproduct (quinon) wan-
neer het beschermt tegen vrije radicalen. Dit monoHER quinon is reactief met 
thiolen, het reageert met glutathion (GSH) waarbij een GSH-monoHER adduct 
wordt gevormd. Opheldering van de structuur van dit adduct met MS en 1H 
NMR toonde aan dat GSH op de C2’ plaats in de B ring van het monoHER quinon 
bindt, waardoor het als 2’-GSH-monoHER geïdentificeerd werd. Moleculair 
kwantum chemische berekeningen toonden aan dat het C2’ atoom van het 
monoHER quinon de hoogste LUMO (laagst onbezette moleculaire orbitaal) 
waarde heeft. Dit verklaart dat het C2’ atoom de meest waarschijnlijke plaats is 
voor nucleofiele aanval van GSH. Het GSH-monoHER adduct werd ook terugge-
vonden in de galvloeistof van een gezonde vrijwilliger die monoHER kreeg toe-
gediend via een intraveneus infuus. Voor zover wij weten, zijn wij de eersten die 
een GSH-flavonoïde adduct hebben gedetecteerd in vivo. De vorming van het 
elektrofiele monoHER quinon is mogelijk schadelijk omdat het, wanneer het 
met GSH reageert, de GSH concentraties en dus het antioxidant verdedigings-
mechanisme verlaagt. Bovendien wordt verondersteld dat het quinon, naast 
t
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GSH, ook met essentiële thiolgroepen van eiwitten, zoals enzymen, kan reage-
ren. Het veronderstelde positieve effect van monoHER als antioxidant kan dus 
worden overschaduwd door de vorming van quinon producten met een elektro-
fiel en potentieel toxisch karakter. 
In Hoofdstuk 3 werd de reactiviteit van het 2’-GSH-monoHER adduct bestu-
deerd en vergeleken met dat van het 6- of 8-GSH-quercetine adduct. Er werd 
gevonden dat GSH-quercetine met het thiol N-acetyl-L-cysteine (NAC) reageert, 
waarbij NAC-quercetine wordt gevormd. Het GSH-monoHER adduct daarente-
gen reageerde niet met NAC. Bovendien werd gevonden dat het adduct van het 
monoHER quinon met de dithiol dithiothreitol (DTT) relatief stabiel is, terwijl 
het DTT-quercetine adduct snel wordt omgezet in quercetine en DTT disulfide. 
Deze verschillen in reactivitieit van de thiol-flavonoïde adducten tonen aan dat 
GSH-monoHER veel stabieler is dan GSH-quercetine. Dit verschil in reactiviteit 
werd bevestigd door moleculair kwantum chemische berekeningen. Hoewel 
beide quinonen van monoHER en quercetine snel ingevangen worden door 
GSH, is het voordeel van monoHER t.o.v. quercetine dat het een stabiel adduct 
vormt met GSH en daarbij de mogelijke verspreiding van toxiciteit voorkomt. 
Deze bevindingen tonen aan dat zelfs flavonoïden met een zeer vergelijkbare 
structuur zich veschillend gedragen. Dit kan tot uiting komen in de biologische 
effecten van deze flavonoïden. 
Om schade veroorzaakt door reactieve oxidatieproducten van antioxidan-
ten te voorkomen, heeft het menselijk lichaam een intrinsiek netwerk van anti-
oxidanten, die op een gecontroleerde manier de reactiviteit van het ene naar 
het andere antioxidant overbrengen. Op deze manier wordt de reactiviteit van 
het radicaal geleidelijk verminderd en worden de antioxidanten telkens terug 
gevormd. In Hoofdstuk 4 werd onderzocht hoe monoHER in dit antioxidantnet-
werk past. Deze positie werd vergeleken met die van quercetine. Zowel het 
monoHER quinon als het quercetine quinon zijn reactief met thiolen van zowel 
GSH als eiwitten. In humaan bloed plasma, dat bijna geen GSH bevat, reageert 
geoxideerd quercetine echter snel met eiwitthiolen, terwijl geoxideerd mono-
HER niet met plasma eiwitthiolen reageert. Dit kon worden verklaard door de 
aanwezigheid van vitamine C in plasma. Vitamine C is in staat het geoxideerde 
monoHER te reduceren tot monoHER voordat het geoxideerde monoHER met 
thiolen kan reageren. Dit is in tegenstelling met het geoxideerde quercetine dat 
eerder met thiolen reageert dan met vitamine C. Het verschil in deze selectivi-
teit tussen monoHER en quercetine, komt door een intrinsiek verschil in de 
chemische aard van hun oxidatieproducten. Dit werd bevestigd door moleculair 
kwantum chemische berekeningen. De reactiviteit wordt door de twee bestu-
deerde flavonoïden op verschillende manieren gereguleerd. Het voordeel van 
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monoHER is dat het de reactiviteit van de radicalen veilig het antioxidantnet-
werk in kan sturen, zodat de reactiviteit geneutralizeerd wordt. Dit toont we-
derom aan dat structuur gerelateerde flavonoïden, die tot dezelfde subgroep 
behoren en een vergelijkbare radicaal vangende activiteit hebben, een heel 
verschillende impact op de gezondheid kunnen hebben. 
Antitumor effect van monoHER 
De resultaten van de klinische fase II studie, waarin de beschermende effecten 
van monoHER op doxorubicine geïnduceerde cardiotoxicitieit geëvalueerd wer-
den, suggereren dat monoHER het antitumor effect van doxorubicine in weke 
delen sarcomen versterkt. Dit effect werd in vitro verder onderzocht door ge-
bruik te maken van weke delen sarcomen cellijnen (Hoofdstuk 5). In één (WLS-
160) van de vier onderzochte cellijnen, versterkte monoHER het antitumor ef-
fect van doxorubicine. In deze cellijn bleek het effect van monoHER gemedieerd 
te worden door de inductie van apoptose. Omdat monoHER in staat is een GSH-
monoHER adduct te vormen, werd er onderzocht of monoHER het GSH-niveau 
in de weke delen sarcomen cellijnen kan verlagen. In tegenstelling tot de be-
kende GSH verlagende stof, L-buthionine sulfoximine (BSO), had monoHER geen 
significante invloed op de GSH-niveaus in deze kankercellen. Dit suggereert dat, 
in tegenstelling tot de GSH-depletie die werd waargenomen in sommige kan-
kercellen veroorzaakt door enkele andere flavonoïden, de groeiremmende ef-
fecten van monoHER in WLS-160 cellen niet gemedieerd werden door GSH de-
pletie. Het is bekend dat vele chemotherapeutische middelen de transcriptie-
factor NF-κB activeren, hetgeen resistentie tegen deze middelen veroorzaakt in 
kankercellen. Zo activeerde doxorubicine ook snel NF-κB in WLS-160 cellen, wat 
voorkomen werd door monoHER. Vermindering van NF-κB activatie door mo-
noHER zou dus verantwoordelijk kunnen zijn voor het gevoelig maken van deze 
kankercellen voor doxorubicine. Uit deze studie kan geconcludeerd worden dat 
monoHER de chemotherapie voor bepaalde patiënten met een weke delen 
sarcoom mogelijk kan verbeteren. Vervolgonderzoek moet aantonen of mono-
HER ook waardevol kan zijn voor de behandeling van andere tumoren die resis-
tentie ontwikkeld hebben via NF-κB activatie. 
Metabolisme van monoHER in muis en mens 
In muizen werd monoHER met succes gebruikt als een beschermer tegen 
doxorubicine geïnduceerde cardiotoxiciteit. Het merendeel van monoHER is 
echter al verdwenen uit het lichaam op het moment dat de doxorubicine con-
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centraties nog hoog zijn. Dit suggereert dat, naast monoHER zelf, ook monoHER 
metabolieten betrokken kunnen zijn bij het vastgestelde hartbeschermende 
effect van monoHER in muizen. In Hoofdstuk 6 werd het metabolisme van mo-
noHER onderzocht door de galvloeistof van muizen, die monoHER kregen toe-
gediend, te verzamelen. Dit leidde tot de karakterisatie van dertien verschillen-
de metabolieten. De volgende metabole routes van monoHER werden waarge-
nomen: methylering, glucuronidering, oxidatie van de hydroxyethyl groep, GSH 
conjugatie en hydrolyse van het disaccharide. Op grond van bevindingen met 
andere flavonoïden wordt verwacht dat gemethyleerd monoHER en de mono-
HER glucosiden een relatief hoge cellulaire opname en relatief lage klaring uit 
het lichaam hebben. Het is daarom aannemelijk dat deze metabolieten kunnen 
bijdragen aan de waargenomen bescherming van monoHER tegen doxorubicine 
geïnduceerde cardiotoxiciteit. 
De in muizen gevonden bescherming van monoHER tegen doxorubicine ge-
ïnduceerde cardiotoxiciteit kon niet duidelijk worden bevestigd in de klinische 
fase II studie met kankerpatiënten met een gemetastaseerde ziekte. Mogelijk 
worden monoHER metabolieten, die bijdragen tot de bescherming, wel ge-
vormd in muizen, maar niet (of in mindere mate) in mensen. Daarom werd het 
monoHER metabolisme ook onderzocht in de galvloeistof van gezonde vrijwilli-
gers (Hoofdstuk 7). In deze mensen werden dezelfde metabolieten teruggevon-
den als eerder in muizen. De relatieve hoeveelheden van de metabolieten ver-
schilden wel in hoge mate tussen beide soorten. De belangrijkste metabole 
route in muizen bleek methylering te zijn, terwijl in mensen vooral glucuronide-
ring werd waargenomen. Methylering maakt flavonoïden lipofieler, waardoor 
ze beter over biologische membranen getransporteerd kunnen worden en hun 
cellulaire opname verhoogd wordt. Het is daarom aannemelijk dat de gemethy-
leerde metabolieten van monoHER bijdragen aan het hartbeschermende effect 
van monoHER, dat werd waargenomen in muizen. Glucuronidering, daarente-
gen, vermindert de opname in de cel en versnelt de eliminatie. De geglucuron-
ideerde metabolieten zullen daarom niet bijdragen aan het hartbeschermende 
effect van monoHER. Bovendien werden er in muizen, in tegenstelling tot in 
mensen, meer monoHER metabolieten gevormd die een vrije glucose groep 
bevatten (monoHER glucosiden). Verondersteld wordt dat deze metabolieten 
actief worden opgenomen door hartcellen via glucose transporters, wat de 
intracellulaire antioxidant concentratie verhoogt en dus bijdraagt aan het be-
schermende effect van monoHER. Uit deze studie kon geconcludeerd worden 
dat het verschil in het metabole profiel tussen muis en mens mogelijk de ver-
schillende biologische activitieit van monoHER in beide species verklaart. 
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Implicaties en verder onderzoek 
MonoHER en de metabolieten van monoHER zijn goede kandidaten voor verder 
onderzoek. Aan de positieve eigenschappen van monoHER, die werden be-
schreven in het inleidende hoofdstuk, heeft het onderzoek beschreven in dit 
proefschrift er nog enkele toegevoegd. Zo kan het oxidatieproduct van mono-
HER (in tegenstelling tot dat van quercetine) gemakkelijker gereduceerd wor-
den tot monoHER waardoor het minder schadelijk is, monoHER kan NF-κB acti-
vatie verminderen in bepaalde kankercellen en verondersteld wordt dat be-
paalde monoHER metabolieten bijdragen tot de hartbescherming en mogelijk 
de antitumor activiteit.  
Er staan daarom verschillende interessante onderzoekslijnen open voor de toe-
komst: 
• Wat het antitumor effect van monoHER betreft, zou het interessant zijn om 
te onderzoeken of monoHER, naast de bestudeerde liposarcoma WLS-160, 
ook andere tumoren, die resistentie voor chemotherapie ontwikkeld heb-
ben door NF-κB activatie, terug gevoeliger kan maken voor chemotherapie. 
• Het zou ook waardevol zijn om de antioxidant en antitumor activiteiten van 
de nieuw geïdentificeerde monoHER metabolieten te onderzoeken. 
• Veelbelovende actieve metabolieten kunnen dan verder onderzocht wor-
den in ons tumordragende naakte muizenmodel. 
• Gebaseerd op de veronderstelling dat de gemethyleerde metabolieten van 
monoHER het hart beschermen, zou het interessant zijn om deze stoffen te 
onderzoeken in ons muis atrium model en om de farmacokinetiek van de 
actieve metabolieten te bepalen in plasma en hartweefsel van muizen. 
• In een volgende stap zullen de hartbeschermende metabolieten onderzocht 
moeten worden in muizen, in vivo. 
• Als de resulaten veelbelovend zijn, kan het antitumor en/of hartbescher-
mende effect van de monoHER metabolieten klinisch worden onderzocht. 
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Eindelijk! Mijn boekje is klaar! Ik was echter nooit zover gekomen zonder de 
hulp van een groot aantal mensen. Daarom wil ik in dit laatste hoofdstuk ieder-
een bedanken die op de een of andere manier heeft bijgedragen aan de tot-
standkoming van dit proefschrift en de fijne promotietijd. 
 
Allereerst wil ik mijn promotor Prof. dr. A. Bast en copromotores Dr. 
G.R.M.M. Haenen en Prof. dr. W.J.F. van der Vijgh bedanken voor de kans die ze 
me hebben gegeven om dit promotieonderzoek te starten. Beste Aalt, bedankt 
voor je enthousiaste en motiverende begeleiding! Ik apprecieer het erg dat je 
elke week weer tijd vrij wist te maken om samen met Guido de resultaten (en 
vaak ook andere dingen..) te bespreken. Je hield onze onderzoekslijn altijd goed 
in de gaten en je zorgde voor de juiste bijsturing en advies op het juiste mo-
ment. Beste Guido, ik kan me geen betere directe begeleider voorstellen dan 
jou. Bedankt dat je deur altijd voor me open stond. Ondanks je drukke agenda 
wist je toch altijd tijd vrij te maken om data te bekijken, mee te denken aan 
proefopzetten en je kennis te delen. Ook bedankt voor het snelle corrigeren van 
manuscripten. Als ik je weer eens ‘huiswerk’ mee gaf, lag het ’s morgens, voor-
zien van jouw commentaren, al weer terug op mijn bureau. Bedankt voor je 
toewijding en uitstekende begeleiding! Beste Wim, ik bewonder uw passie en 
grenzeloze enthousiasme voor onderzoek. Ook al had u geen vaste werkplek in 
Maastricht, via e-mail, telefoon, post, fax en natuurlijk uw regelmatige bezoek-
jes aan Maastricht wist u mij toch een bijzonder goede begeleiding te geven. 
Mede dankzij uw zorgvuldigheid en kritische kijk, hebben we mooie resultaten 
bekomen. Hiervoor wil ik u hartelijk bedanken. 
Aalt, Guido en Wim, ik heb veel van jullie geleerd. Jullie zijn een geweldig pro-
motieteam! 
 
Ik had het geluk om tijdens mijn promotieonderzoek samen te mogen wer-
ken met verschillende mensen uit verschillende vakgebieden. 
Dr. G.H. Koek (AzM, Maastricht), beste Ger, bedankt voor je hulp bij de humane 
studie in Leuven. Door jouw ervaring verliep het verzamelen van de gal bij de 
proefpersonen bijzonder gesmeerd! Ook wil ik graag Prof. dr. J. Tack, Rita Vos 
en Lieselot Holvoet (Gasthuisberg, Leuven) bedanken voor hun hulp bij deze 
studie. En natuurlijk ook alle vrijwilligers die bereid waren aan deze studie deel 
te nemen. 
Dr. R. Peters (DSM Resolve, Geleen), beste Ron, bedankt voor alle hulp bij de 
LC-MS analyses. Voor de identificatie van de verschillende monoHER metabolie-
ten was jouw kennis onmisbaar. Het was gezellig om een paar dagen bij jullie op 
het lab door te brengen. Leuk dat je nu ook in mijn beoordelingscommissie zit! 
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Dr. G.P.F. van Strijdonck (Hoge school Zuyd, Heerlen), beste Gino, jou wil ik 
samen met je toenmalige student Guy Draaisma graag bedanken voor de hulp 
bij de identificatie van het GSH-monoHER adduct. Dit heeft een mooie publica-
tie opgeleverd! 
Prof. dr. G.J. Peters (VU, Amsterdam), beste Frits, hartelijk bedankt voor het 
aanleveren van de humane cellijnen en uw hulp bij het schrijven van het cel-
kweek artikel. Ook dit leidde tot een mooie publicatie!  
 
Ik wil ook graag alle leden van de beoordelingscommissie hartelijk bedan-
ken voor het beoordelen van mijn proefschrift. 
 
Vervolgens wil ik graag mijn Toxicologie collega’s bedanken voor de aange-
name werksfeer en de geweldig leuke tijd de afgelopen jaren. Om zeker 
niemand te vergeten ga ik best even één voor één alle kamers af. Ik heb mijn 
eigen kamer mogen delen met verschillende toffe mensen. Els, mijn allereerste 
kamergenootje, ik weet nog goed hoe ik viereneenhalf jaar geleden als AIO 
kwam binnenwandelen. Je was toen zelf druk bezig met alles te regelen voor je 
eigen promotie. Toch vond je regelmatig de tijd voor een gezellige babbel. Be-
dankt om me zo goed op te vangen, mede dankzij jou voelde ik me direct thuis 
op onze afdeling. Na een tijdje werd het iets ‘drukker’ op onze kamer.. Agnes, 
we zijn maar kort kamergenootjes geweest, maar het was een leuke tijd! Fijn 
dat je nu weer terug in Maastricht werkt. En dan mijn twee huidige kamerge-
nootjes, Daniëlle en Bregje. Het is echt gezellig bij ons op de kamer (Zou ons 
plantje daar voor iets tussen zitten? Of jullie regelmatige meezingen met de 
radio? Of zou het toch komen door onze gezamenlijke jeugdidolen ;-)...) Daniël-
le, jou moet ik nog extra bedanken voor het dagelijks ophalen van onze post. Zo 
bezorgde je me onlangs net op tijd een toch wel belangrijke brief ;-)  
Dan onze twee toffe buurvrouwen, Jiska en Merel. Jiska, bedankt voor je luiste-
rende oor en de handige promotietips. Merel, bedankt voor de gezelligheid 
(wanneer gaan we die cocktails nu nog eens shaken?).  
De volgende kamer is al vaak van eigenaar veranderd. Eerst Saskia, Liesbeth en 
Erik C (zelf een kersverse doctor). Ondertussen druk bezet door: Nuria (graci-
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nog gezond ook.. toch?) en Max, jij verdient nog een speciaal woordje van dank 
voor alle hulp bij de chemische aspecten van mijn proefschrift, van Spartan 
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gelach uit die richting komen. Antje (bedankt voor al je kritische vragen tijdens 
onze werkbesprekingen) en Gertjan (nogmaals bedankt voor je hulp bij de mui-
zenstudie). 
En dan, last but not least, volgens mij de drukst bezochte kamer van onze afde-
ling (door mij in ieder geval toch..). Marie-José, Roger, Esther (en vroeger ook 
Marc en Vanessa), bedankt dat ik altijd bij jullie terecht kon als ik weer eens 
ergens hulp bij nodig had of gewoon voor een gezellige babbel. Marie-José, 
bedankt voor je helpende hand op het lab! Marc, bedankt voor me wegwijs te 
maken met de HPLC en voor de hulp bij het opzetten van mijn eerste HPLC me-
thode. Vanessa, je was een toffe collega! Esther, DUS.. het is altijd gezellig met 
jou in de buurt (eetmaatje, feestmaatje,..), bedankt voor de leuke koffiepauzes, 
je behulpzaamheid en interesse. Roger, bedankt voor al je hulp, je gezelligheid 
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Dan nog een speciaal woordje van dank voor mijn paranimfen, Els en Roger. 
Eerst en vooral heel erg bedankt dat jullie mijn paranimfen willen zijn. Echt fijn 
dat jullie op 1 juli naast mij zullen staan! Ik heb jullie daarnet al even genoemd. 
Maar, ook buiten het werk hebben we al verschillende leuke dingen gedaan. 
Denk maar aan de ooh zo foute Q-party’s en andere feestjes. En natuurlijk onze 
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over voor familie en vrienden. 
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en feestjes. Binnenkort is het onze beurt om een BBQ te organiseren. Echt fijn 
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Mijn lieve schoonfamilie: Martine, Daniel, Tiffany, mémé en bonpoes. Be-
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Bomma en Bompa, hoe kan ik jullie ooit bedanken voor alles wat jullie voor 
mij gedaan hebben.. Bedankt dat ik altijd bij jullie terecht kan en voor jullie 
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zo lang heb mogen genieten van jullie warme nest. En natuurlijk ook Leedy en 
Lara (de liefste honden van de hele wereld), bedankt voor het altijd even en-
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